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Abstract 
Naïve pluripotent embryonic stem cells (ES cells) have the ability to give rise to 
all cell types including functional gametes. These cells have been well established 
in mice and rats. The potential for biomedical and agricultural applications of 
pluripotent stem cells in livestock are vast. Having this resource will make in vitro 
techniques more achievable for research purposes and commercial use. Their use 
for chimera formation will increase the production of high quality embryos, 
resulting in a faster inclusion of desirable traits in breeding lines.  
 
The aim of this study was to investigate the molecular characteristics of 
pluripotency in bovine embryos. This is an incremental step to aid our 
understanding of the greater system which will encourage the derivation of ES 
cells within the bovine species. An initial target was the key pluripotency 
transcription factor NANOG. Nanog has thousands of targets and orchestrates the 
regulation of the naïve pluripotent molecular environment. This thesis will 
investigate the overexpression of NANOG with a doxycycline-inducible system in 
bovine female fibroblasts and nuclear transfer (NT) embryos derived from these. 
It was hypothesised that the overexpression of NANOG would stimulate the 
pluripotency network, increasing pluripotency. It has previously been recognised 
that the re-activation of the X-chromosome in females is an indicator of naïve 
pluripotency in mouse. Notably, the gene Xist which is important for the 
inactivation of the X-chromosome is directly repressed by Nanog. It was 
hypothesised that this would hold true in the bovine system.  
 
Both the cell line and embryos were analysed for mRNA and protein expression 
of ectopic NANOG using quantitative PCR (qPCR) and immunocytochemistry. 
Eight pluripotency-related genes (endogenous NANOG, OCT4, SOX2, KLF4, 
PDGFRα, SOX17, SOCS3 and FGF4) were quantified using qPCR to investigate 
the impact of increased NANOG in the NT embryo at day 8.  Expression of XIST 
mRNA was analysed using qPCR and the inactive X-chromosome was identified 
using immunocytochemistry to understand the role of NANOG in the 
re-activation of the X-chromosome in the bovine system.  
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It was found that the inducible system significantly increased the expression of 
ectopic NANOG mRNA and protein within the fibroblasts used for NT. A two-
fold significant increase of total NANOG mRNA was achieved in the NT embryo, 
although no additional NANOG protein was identified. The increased NANOG 
had no effect on the eight pluripotency-related genes investigated. The increased 
NANOG had no effect on the expression of XIST in the bovine system. No 
inactive X-chromosomes were identified via immunocytochemistry during this 
project. Subsequent to this research, details of an alternative overexpression 
technique using CRISPR technology were published. Use of this system will 
make research in this field achievable to a higher quality in a shorter timeframe.  
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 Literature Review Chapter 1:
 The discovery of stem cells 1.1
A stem cell is an undifferentiated cell which has not specialised into a cell type. A 
pluripotent stem cell can develop into any cell type in the body and can proliferate 
indefinitely. Pluripotency occurs during the reprogramming of the genome; it 
wipes the epigenetic history and allows a fresh start for the genome to begin 
development of a new organism. In 1981, the first embryonic stem (ES) cells were 
derived from 3-4 day old mouse (Mus musculus) embryos. In theory, a developing 
embryo must go through a phase of pluripotency to allow the subsequent 
development to occur; this event should take place across all animal species. 
However, only mouse has shown naïve pluripotency. Naïve pluripotency is stably 
pluripotent as opposed to primed pluripotency in which the cells is more 
responsive to differentiation cues. Most species investigated have only 
demonstrated putative pluripotency (Figure 1). 
 
The first population of ES cells was derived from the inner cell mass (ICM) of a 
pre-implantation mouse blastocyst. All mammalian embryos have a blastocyst 
phase and go through the same initial developmental pattern. After initial 
fertilisation of the mammalian oocyte, the cytoplasm begins to cleave. It goes 
through a series of stages, 2, 4, and 8-cell, at which point the cells compact and 
form a tight morula [1] (Figure 1). A fluid-filled cavity is then formed and some 
cells compact into a small cluster known as the ICM [1] (Figure 1). The 
trophoblast will develop into the placenta, where the ICM is comprised of two 
populations of cells; the hypoblast and the epiblast. The hypoblast forms 
extra-embryonic components whereas the epiblast forms the embryo proper [1]. 
These populations are molecularly distinct from one another within the ICM. This 
development is similar across mammalian species. However, it differs in the 
duration of each stage (Figure 1). It is not until after the development of the 
blastocyst that there is a morphological distinction between species.  
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Figure 1: Early embryonic developmental stages of mouse and cattle in relation to 
its pluripotent state. Adapted from [1]. 
For a cell to achieve pluripotency status there are three validating assays. The first 
assay to verify pluripotency is to investigate the cells ability to develop into a 
teratoma, a tumour containing the germ layers mesoderm, ectoderm and endoderm. 
In this assay, the ES cell is placed in vivo and analysed for its abilities to derive 
cells from all three germ layers. The next assay is the chimera assay which tests 
the ES cells ability to contribute to an embryo once injected. This results in the 
creation of a chimera, where the organism contains two separate genomes. Cells 
that have a high pluripotentiality can also form germline chimeras in which the ES 
cell contributes to the formation of the germline. This is a more stringent assay as 
the germline is established prior to gastrulation of the three germ layers. The final 
and most rigorous assay is the tetraploid complementation assay which involves 
the combination of a tetraploid and a diploid embryo. A positive assay would 
result in an embryo that is completely comprised of the diploid genome where the 
extraembryonic tissue is derived from the tetraploid genome.  
 
The search for the existence of these cells in other species intensified after the 
mouse ES derivation. In 1998, human ES cells were derived when the cells 
achieved the successful formation of a teratoma, suggesting they are pluripotent 
[2]. However, scientists still remain sceptical about their validity since chimera 
and tetraploid complementation assays were not completed. Due to the nature of 
these experiments, ethical boundaries prevent them from ever being conducted in 
the human species [3]. Therefore, the human ES cell cannot be truly validated as 
naïvely pluripotent. These three tests are considered ethically acceptable in 
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mammalian species other than human. However, ES cells derived from other 
species do not have the capacity to successfully achieve these assays. 
 
When the mouse ES cell was derived it was found to require serum and mouse 
embryonic fibroblasts (MEFs) as feeder cells, which provided optimal culture 
media for the maintenance of pluripotency [4]. It was later discovered that the 
essential component produced by the feeders was leukemia inhibitory factor (LIF) 
[5,6]. Also, it was discovered that the serum could be replaced with bone 
morphogenetic proteins (BMPs), and in combination with feeder cells improve ES 
cell culture conditions [7]. These conditions have been attempted in the culture of 
other species’ ES cells and have failed to stimulate pluripotency and allow 
indefinite cell proliferation. It is clear that these conditions are optimised for 
mouse ES cell growth and need to be modified to improve the culture conditions 
that support pluripotency in other species. 
 
Recently, rat (Rattus rattus) ES cells have achieved all three pluripotency 
validating assays [8,9]. Thus, mouse and rat are the only animals to date that have 
demonstrated true pluripotency in vitro. Although it was initially believed that the 
ES cell requires extrinsic cues to promote the self-renewal pathways involved [10], 
it was later discovered that the ES cell also requires the block of the 
differentiation pathways to remain in a pluripotent state [11]. This resulted in the 
development of a variety of culture medias engineered to do so, such as 3i (three 
inhibitors). This contains the inhibitors for three cellular pathways, the three 
molecules; PD184352, PD173074 and CHIR99021. The CHIR99021 component 
is a small molecule inhibitor of glycogen synthase kinase 3 (GSK3) [12] which is 
a part of the Wingless-Type MMTV Integration Site Family Member (WNT) 
pathway. Whereas PD173074 and PD184352 are pharmacological inhibitors of 
fibroblast growth factor (FGF) [13] and mitogen-activated protein kinase (MEK) 
which is within the FGF pathway [14]. This media has allowed the production the 
rat ES cell, which have achieved true pluripotency. Unfortunately, this treatment 
was not as successful when applied in other species but does demonstrate the 
notion that the molecular environment of the cell can be modified to achieve the 
pluripotent status. 
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Over all after decades of research, these cells have really only been developed in 
mouse, rat and human. To truly understand pluripotency, the understanding of the 
molecular pathways involved must be extensively characterised, along with how 
these function to develop and maintain the pluripotent state.  
 Development and maintenance of pluripotency 1.2
The molecular mechanisms in place to develop and maintain the pluripotent state 
have been thoroughly investigated in the mouse model yet they are not greatly 
understood. There are four key extrinsic stimuli which activate four pathways that 
are known to play a role in the establishment and maintenance of pluripotency in 
the mouse model. These are BMP, LIF, FGF and WNT. They promote either self-
renewal or differentiation by regulating the transcription of the three essential 
pluripotency regulators, SRY (Sex Determining Region-Y) Box-2 (Sox2) [15], 
Octamer Binding Transcription Factor-4 (Oct4) [16] and Nanog homeobox 
(Nanog) [17-19]. These factors are regulated depending on the stage of pluripotent 
development [20], which is governed by the four pathways involved. 
 
Boosting the LIF pathway ultimately causes an up-regulation in the three key 
pluripotency regulators, which in turn increases the pluripotency of a cell. The 
BMP pathway acts by forming a balance between the FGF signalling and LIF 
signalling which maintains pluripotency by blocking ES cell neural differentiation 
[21]. The pathway FGF is involved in a number of processes such as cell survival, 
migration, proliferation and differentiation [22]. The FGF pathway also plays a 
role in lineage segregation within the embryo and ultimately also is one of the key 
regulators of pluripotency. When the FGF/extracellular signal-regulated kinases 
(ERK) pathway is inhibited, ES cells are able to maintain their pluripotency [23]. 
The FGF pathway is involved in the transition from the naïve pluripotency state, 
into the primed pluripotency state. The primed pluripotency state is a population 
of cells specific to the epiblast which do express many of the pluripotency 
indicators. However, they cannot achieve the stringent experimental requirements 
that naïve stem cells can [24]. This pathway is the key pathway involved in the 
transition into differentiation and is therefore a target for inhibition, in attempts to 
sustain pluripotency. Finally, the WNT pathway which regulates the 
differentiation of the cell into the three germ layers, has also been shown to 
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regulate self-renewal [25]. The activation of WNT results in an up-regulation of 
the three pluripotency regulators [26].  
 
These four pathways have an impact on the regulation of Oct4, Sox2 and Nanog. 
This triumvirate orchestrate thousands of target genes [27]. When this network is 
functioning the differentiation genes are switched off and the self-renewal genes 
are switched on. The reverse is true when this network is switched off [20,27]. 
Within the Nanog, Oct4, Sox2 network are a series of feedback loops. The Nanog 
protein binds to the promoter regions of Sox2 and Oct4, as well as binding to its 
very own promoter region which can either result in expression or suppression of 
itself (Figure 2). Oct4, Sox2 and Nanog are also individually regulated by the 
Oct4 and Sox2 heterodimer (Figure 2). This results in a core of transcription 
regulation (Figure 2). 
 
Figure 2: Core transcription factor network’s regulation of pluripotency or 
differentiation. A and B represent two different pathways involved (Either LIF, BMP, 
FGF or WNT). In this example when A and B are switched on (+), the network is 
switched on resulting in the up-regulation of stem cell related genes and the intricate 
feedback loops of this system maintain pluripotency. Alternatively, A and B are switched 
off (-), it blocks Nanog’s function and the core network dissolves resulting in 
differentiation [20]. 
With a greater knowledge of these mechanisms, other techniques such as 3i 
culture could be developed, allowing a greater potential to achieve the correct 
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culture conditions for ES cells for a variety of species. Many of these molecular 
markers described can be used in the identification of the time point in embryo 
development for pluripotency. This method allows research teams to hone in on a 
point in development which is more likely to achieve the culture of a truly 
pluripotent cell. A candidate molecular indicator for the development of 
pluripotency is X-chromosome inactivation.  
 Nanog’s role in pluripotency 1.3
Although Nanog is not one of the genes required to maintain pluripotency [28,29], 
it is still heavily involved in “ground state pluripotency” [17]. It has also been 
theorised that Nanog may be the gene which initiates the development of 
pluripotency and may act as a transcriptional organiser of the other key 
pluripotent factors [30]. However, it is not required to maintain pluripotency once 
it has been established [17]. This was shown when Nanog was not required during 
dedifferentiation in the establishment of induced pluripotent stem cells (iPS cells) 
[28,29] but is the “gate keeper” for transition into “ground state” or naïve 
pluripotency in both ES and iPS cells [31]. When Nanog was removed from the 
mouse system the ICM was unable to generate an epiblast, and was incapable of 
maintaining pluripotency and differentiated into endoderm like cells [19].  
 
In 2003, a group led by Professor Austin Smith from the University of Cambridge, 
identified Nanog [18]. The complementary DNA (cDNA) libraries of ES cells 
were functionally screened, which resulted in the detection of a homeobox gene 
which was only expressed in the early embryo. This homeoprotein was involved 
in cell self-renewal. The group therefore named this gene Nanog, after Tir na nOg, 
the mythological Celtic land of the ever young [18]. In a concurrent study, Dr 
Shinya Yamanaka from Kyoto University, used the in silico differential display 
technique to identify a series of genes that may be involved in pluripotency [19]. 
This was conducted on mouse ES cells and pre-implantation embryos. This also 
resulted in the discovery of the homeoprotein Nanog [19]. It was found that this 
protein allowed the cells to self-renew even in the absence of LIF [19,32]. In 
addition, when Nanog was deficient, the ICM did not generate an epiblast and in 
ES cells with Nanog deficiency, pluripotency could not be maintained, so the cells 
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differentiated [19]. This indicated that Nanog was essential in the development 
and maintenance of pluripotency [19]. 
  
After these two initial studies highlighted the significance of Nanog in the 
pluripotent system, the investigation of its finer workings within the system began. 
Surprisingly, the generation of iPS cells did not require Nanog to induce 
pluripotency [28,29], However, Nanog is important in the development of naïve 
pluripotency or “ground state” pluripotency, by orchestrating the core 
pluripotency factors to bind to their ES cell targets [31]. This is why Nanog was 
dubbed the “gatekeeper’ of pluripotency. The next challenge was to understand if 
this models function is conserved across species.  
 
When Nanog was removed from human ES cells via RNA interference (RNAi), 
there was an increase in the expression of genes associated with the 
extraembryonic endoderm and trophectoderm [31]. Alternatively, when Nanog 
was overexpressed in human ES cell culture it allowed the cells to propagate over 
a number of passages without the need for feeder cells. The Nanog overexpressing 
cells also no longer required media conditioned by MEFs which were usually 
required to provide the right environment for the cells to grow [33]. This is an 
indication that at least some of the workings of the Nanog system are conserved 
across mammalian species.  
 
The function of NANOG in bovine is very similar to its role in the mouse model 
system. Again it is expressed in the bovine blastocyst in the ICM [34]. NANOG 
was also up-regulated from the morula to the blastocyst phase [35] and has a 
mosaic form of expression at day 7 [36] similar to that in mouse. It was also found 
that use of the 2i treatment (a treatment similar to 3i with two inhibitors) in bovine 
significantly up-regulates the expression of NANOG [37,38]. This indicates that 
NANOG’s role in pluripotency is conserved throughout mammalian species and 
within the bovine system.  
 
Nanog regulates the expression of thousands of genes by binding to their 
promotor regions [39]. The studies analysing the structure of the Nanog protein 
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elucidated how this function was preserved. The Nanog protein has three 
functional domains [40]. There is a homeodomain, which allows it to control the 
expression of other genes spatially and temporally [41]. The homeodomain is a 60 
amino acid sequence which the protein uses to bind to its targets. This domain is 
highly conserved between vertebrate species [41].The Nanog homeodomain was 
found to bind to the TAAT(G/T)(G/T) motif [40]. Nanog also contains N and C 
terminal regions [40]. It has been confirmed that both regions undertake 
transcriptional actions [42]. The N terminal region is less active than the C 
terminal region seven-fold. This distinctive organisation of transactivators may 
allow Nanog to achieve the specificity and plasticity to interact with genes 
involved in pluripotency and differentiation [42]. There are multiple isoforms of 
Nanog found in the ES cell due to alternative splicing. In mouse, the longest 
isoform reported is a 2185 bp messenger RNA (mRNA) transcript encoding 305 
amino acid protein [41] with a molecular weight of 34 kDa [43]. The Nanog 
protein has a brief half-life of 120 minutes [44] which allows tight regulation 
within the ES system. 
 
Nanog plays a role in the four extrinsic signals relevant to the pluripotency 
network, LIF, FGF, BMP and WNT [45]. This was shown when increased levels 
of Nanog can allow human ES cells to grow feeder free [33] and mouse ES cells 
to be maintained without LIF [19]. There are also intrinsic pathways in which 
Nanog is involved such as the pluripotency trio Nanog, Oct4 and Sox2 [20]. 
Another important target of Nanog is Xist and their partnership in the re-activation 
and inactivation of the X-chromosome [46].  
 X-chromosome inactivation 1.4
There are a number of features of ES cells which can be used to identify whether 
they are truly pluripotent. One of these is double X-chromosome activation [31]. 
This is a stage of the process of X-chromosome inactivation [47]; a method of 
epigenetic silencing of the X-chromosome that has been extensively analysed in 
the mouse. This mechanism is required in female mammals as a form of dosage 
compensation for X-chromosomal genes which are only expressed from one 
X-chromosome in male mammals [48,49]. Females must effectively silence one 
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of their X-chromosomes from transcription and translation throughout their entire 
body [48].  
 
There are a number of regulators of the X-chromosome inactivation process. It is 
largely controlled by the X-inactivation centre (Xic) [50] which contains multiple 
long non-coding RNAs (lncRNA) [51] that interact with one another to 
orchestrate the process of X-chromosome inactivation and reactivation. This is 
where the Xist gene is located, which encodes a 17 kb lncRNA which works in cis 
[50,52,53]. Xist forms a cloud around the inactive X-chromosome which prevents 
it from transcription and translation [52]. It does this by orchestrating 
heterochromatin changes, for example the recruitment of the Eed-Enx1 Polycomb 
group complex [54] which is required to establish methylation such as H3K27me3 
[55]. The silencing of the X-chromosome ultimately creates a balance between 
males and females in the expression of X-chromosome genes. Within the Xic also 
lies the Xist antisense Tsix [56]. Tsix is a 40 kb lncRNA, which is transcribed from 
both active X-chromosomes prior to inactivation. The expression of Tsix becomes 
monoallelic at the onset of X-chromosome inactivation and is expressed on the 
future active X-chromosome and cannot be detected on the inactive X-
chromosome [56]. Tsix silences Xist’s promoter and effectively supresses Xist 
expression [57,58]. It would be a simple mechanism if Tsix was the sole repressor 
of Xist and these two genes worked together to activate and inactivate the 
X-chromosomes. However, it has been characterised that there is a lack of Tsix in 
the reactivation of the inactive X-chromosome in the primordial germ cell (PGCs) 
which occurs later in development (Figure 3) [46]. This coupled with the 
suppression of Xist during the development of ES cells (Figure 3) encourages the 
idea that the factors involved in the regulation of pluripotency also play a role in 
the reactivation process via the suppression of Xist expression [46]. 
 
During this process there is a time point in which the silencing of the 
X-chromosome is reversed and for a brief period both X-chromosomes are active 
[59]. This is the result of a genome wide epigenetic wipe, in which all epigenetic 
elements such as methyl groups are removed from the genome as if to refresh the 
genome for its development into a new organism. This wipe also causes a small 
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population of cells to become naively pluripotent [59]. The most obvious marker 
for this event is the disappearance of Xist and its cloud around the inactive 
X-chromosome [59,60]. These clouds are very clear markers leading up to the 
development of ES cells, which disappear for the brief window when ES cells are 
established and develop again soon after. Therefore, with the use of a technique 
such as RNA fluorescence in situ hybridisation (RNA FISH), the process can be 
visualised taking place during the development of an embryo, where the absence 
of the Xist clouds can be used as an indicator for the presence of ES cells [59]. 
The timeline of the mouse X-chromosome inactivation and reactivation is 
illustrated in Figure 3 [46]. 
 
Figure 3: X-chromosome inactivation and reactivation in early mouse embryo 
development. Trophectoderm (TE, in pink), primotive endoderm (PE, in purple), inner 
cells mass (yellow), inactive X (Xi), epiblast (EPI, in orange), primordial germ cells 
(yellow). Image from:[46].   
After initial fertilisation there is an imprinted X-chromosome inactivation. This is 
always the paternal X-chromosome [46] and it remains inactive until the embryo 
reaches the blastocyst phase. At this point, day 3.5 in mouse, the inactive 
X-chromosome switches back on for a brief period before a random 
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X-chromosome is selected and silenced at day 4.5. At the post implantation stage 
(day 6.5), the PGCs develop and again the inactive X-chromosome is reactivated 
until the PGCs have migrated, when finally one X-chromosome is randomly 
inactivated from then on [46].  
 
When the activities of the pluripotency regulating transcription factors are 
evaluated in terms of Xist expression and X-chromosome reactivation, the 
elaborate mechanisms are revealed. It was previously assumed that the 
suppression of Xist and subsequent reactivation of the inactive X-chromosome 
was a by-product of the profound epigenetic reprogramming that occurs during 
pluripotency and was not the primary target [61,62]. However, recently it has 
been established that Oct4, Nanog and Sox2 maintain the suppression of Xist by 
binding to the chromatin of the Xist gene during the development of ES cells [63]. 
Xist is targeted by the pluripotency triumvirate and is actively suppressed during 
pluripotency [46]. The reactivation of the X-chromosome and the pluripotent 
status of the cell are intimately linked in that the stages of reprograming are 
directly related to degree of X-chromosome silencing [64]. 
 
There have been multiple theories as to how this may occur. One of which is 
depicted in Figure 4 [46]. Oct4 and Sox2 are active throughout the earlier 
development then later become more localised to the ICM. The reactivation of the 
X-chromosome does not occur until there is an increase in Nanog expression 
during the development of the blastocyst and the PGCs. This indicates that Nanog 
may be the predominant influence of the repression of Xist [46]. As demonstrated 
by iPS cells, Nanog is not required to maintain pluripotency [28,29]. However, it 
is required to produce the naïve ground state pluripotency seen in ES cells [31]. 
This shows Nanog’s role as a regulator, only required to establish pluripotency 
but not essential to sustain it [46]. This may be the same way in which it acts in 
regards to Xist suppression. This is why the reactivation of the X-chromosome is 
only seen in the Nanog positive cells of the ICM and PGCs [46]. In relation to the 
model (Figure 4), Nanog may be able to bind to Xist intron 1. This could 
orchestrate a remodelling of the chromatin which allows the binding sites for Oct4 
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and Sox2 to be unveiled. Finally, Oct4 and Sox2 can bind to Xist intron 1 and 
actively supress its expression [46]. 
 
Figure 4: One theorised model of Xist repression via the action of the pluripotency 
factors Nanog, Oct4 and Sox2. A) Early cleavage stages express Oct4 (blue) and Sox2 
(green). However, these cannot bind to Xist (black) intron 1 and Xist mRNA expression 
remains high. Oct4 and Sox2 binding sites remain tightly bound around nucleosomes 
(grey) B) As Nanog (red) begins to be expressed it employs chromatin remodelling 
complexes (yellow). C) These restructure the chromatin which exposes the binding sites 
for Oct4 and Sox2. D) Once these have successfully bound to Xist intron 1 Xist is 
repressed.  Image from:[46]. 
In describing the development and maintenance of pluripotency, many of the 
pathways involved had a direct impact on the regulation on the gene Nanog. 
 Nanog’s role in X-chromosome reactivation 1.5
It is clear that the process of X-chromosome inactivation and reactivation is 
intimately linked with pluripotency in the mouse. This is why in these 
experiments the presence of the Xist clouds and its notable absence during the 
development of ES cells was used as an indicator for the function of Nanog and 
the timing of ES cell development in the bovine species. In the mouse, the 
interplay between Nanog expression and Xist expression was demonstrated by a 
team led by Professor Austin Smith in 2009 [31]. At day 3.5, the expression of 
Oct4 and Nanog is stronger in the ICM and trophectoderm (Figure 5). Also at this 
Chapter 1: Literature Review 
 
13 
 
time point, the expression of Eed, a constituent of the Eed-Enx1 Polycomb group 
complex used to establish epigenetic methylations on the inactive X-chromosome, 
is present within each cell throughout the embryo, representing the inactive X-
chromosome. At day 4.5, there is an up-regulation in Nanog expression in a small 
population of cells within the ICM. The correlating cells in the Eed panel no 
longer possess their inactive X-chromosome. Both X- chromosomes are active 
within these cells and this population can be defined as naïve “ground state” 
pluripotent ES cells.  
 
Figure 5: Expression of Oct4, Nanog and Eed at day 3.5 compared with day 4.5. E 
denotes embryonic day Arrows highlighting cells of the ICM. Image adapted from [31]. 
It has also been demonstrated that the increase in expression of Xist via a 
doxycycline-inducible system caused the suppression of the pluripotency 
associated genes, Prdm14, Tcl1 and Nanog [65]. In the same study it was also 
confirmed that the double dosage of X-chromosome genes disrupts differentiation 
[65]. It is clear that the interplay between pluripotency and double X-chromosome 
activation is intimate [64].  
 
It is hypothesised that this extensive link between Nanog and Xist (Eed) (Figure 3) 
may hold true in other species including bovine. Therefore, an analogous image 
using bovine ES cells as depicted in Figure 5 is the objective of the experiments 
conducted for the purpose of this thesis. To accomplish this requires a large 
number of female embryos, which overexpress the gene NANOG. This can be 
achieved via the technique of nuclear transfer (NT) cloning. 
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 The history and utility of nuclear transfer cloning 1.6
In conducting any scientific experiment, it must be clear that the difference 
between the control group and the treatment group can only be a result of the 
treatment and not as a result of other factors. For many fields of research, this 
difference is easy to navigate. The use of identical twins in many human genetic 
studies has been valuable, as they possess the same genomic sequence and 
therefore can be used as control groups for one another [66]. This is where the 
cloning of animals serves the purpose of being able to produce such a set of 
genetically identical individuals for analysis of gene function, epigenetics and 
early developmental events [67].  
 
The NT process is relatively simple in theory. A donor cell containing the desired 
DNA is fused with an unfertilised egg whose DNA was removed. The oocyte is 
then activated and begins normal embryonic development resulting in an adult 
animal [67] (Figure 6). The theory of nuclear transfer experiment was established 
in 1928 by Hans Spemann [68]. It was first put into practice in 1952 in 
experiments conducted by Robert Briggs and Thomas King [69] using embryonic 
blastula cells. The first time a somatic cell was transplanted and successfully 
reprogrammed was by Sir John Gordon in 1958 at the University of Oxford in the 
Xenopus tadpole [70,71]. This was the first time it was demonstrated that an adult 
cell can reprogramme its DNA in order to orchestrate the genetic regulation 
required during embryo development and growth.  This encouraged heavy interest 
in the idea, leading to the first successful mammalian clone, at Roslin Institute in 
Scotland, with the production of Dolly the sheep in 1996 [72]. After this ground 
breaking achievement the number of cloned mammalian species increased, with 
many other species of mammals being successfully cloned [73-85], including the 
first successful bovine clone in 1998 [86,87]. All species have slight 
modifications to the NT method to increase efficiency. The standard method used 
for cow NT is shown in (Figure 6).  
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Figure 6: Somatic cell nuclear transfer method for bovine. 1 a) Skin cells are isolated 
from an adult animal. 1 b) Oocytes retrieved from an adult animal have their zona 
pellucida removed and they are enucleated (2)..Enucleated oocytes are fused with the 
isolate skin cells (3). Normal embryonic development then follows (4). The embryo 
develops into an adult.  
This technique also allows the formation of genetically modified organisms [88] 
which during the culture of somatic cells may be transfected with vectors to 
overexpress or remove genes that are already present or to add genes that are not 
present in that organisms system. This allows the understanding of how that 
specific gene functions during the embryonic development of the organism and 
can elucidate a genes role. Animals that do not have pluripotent ES cells, but do 
have an established NT method, use NT to generate transgenic animals. This has 
become common practise for research in species such as bovine and porcine [88-
90].  
 
NT cloning was employed for the research conducted in this thesis. A transgenic 
cell line was created for the use in NT experiments to analyse the response of the 
overexpression of a gene. The cell line was transfected with a doxycycline-
inducible vector which will be explained in more detail in section 1.7.  
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 Tet-3G system and how it functions 1.7
Numerous techniques can be used to overexpress a gene in the mammalian cell. 
The most efficient technique is the production of the chimera, as explained in 
section 1.9. However, this technique requires the truly pluripotent ES cell, which 
the bovine does not have, thus, a different technique must be employed. Another 
overexpression technique is the use of the Tet-On 3G tetracycline inducible gene 
expression system (Tet-3G system) [91]. This was the system which was 
employed for this research. It uses the antibiotic tetracycline or a derivative 
(doxycycline, which is much more stable) to control gene expression by either 
turning transcription on or off.  
 
This system involves the naturally occurring Tetracycline-repressor (TetR) which 
results in tetracycline resistance for some gram-negative bacteria [92]. TetR 
regulates the expression of TetA (the protein that moves tetracycline out of the 
cell) [92]. The expression of TetA and TetR are blocked by the presence of two 
homodimeric TetR molecules which bind to two DNA operator regions of the 
resistance determinant [92]. When tetracycline is present it forms a stable 
complex with TetR which prevents it from binding to the operators. This allows 
the expression of TetR and TetA. When TetA is present it can then export the 
tetracycline away from the ribosome before it can inhibit ribosomal activity [92]. 
 
This prokaryotic expression system can be used in the eukaryotic cell to induce or 
silence the expression of genes as a part of a vector sequence [93]. Doxycycline is 
simply added to the culture medium of the tissue. It binds to the Tet-On 3G 
transactivator, which as a result binds to the promoter region of the vector and 
commences transcription (Figure 7). The vector sequence can also contain a 
reporter protein, such as monomeric (m) red fluorescent protein (RFP)-reporter 
(mCherry), to indicate induction by visualisation of red fluorescence (Figure 7). 
The internal ribosome entry site (IRES) is located 5’ to the gene of interest which 
allows the translation of the protein to be initiated at this point, resulting in two 
separate protein constructs from a single mRNA sequence [94]. There are a few 
different types of this system that are commercially available, including those 
which switch off expression and others switch on expression when doxycycline is 
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present. The system used for the purposes of this research was the third generation 
(3G) system. This system is an improved system of the method originally 
developed by Hermann Bujard, Wolfgang Hillen and Manfred Gossen. It has 
increased sensitivity and reduced background by the addition of a new 
transactivator protein and promoter [91].  
 
 
Figure 7: The Tet-On 3G system. A. Representation of the system in the absence of 
doxycycline, compared with in the presence of doxycycline. B. The Tet-On 3G system as 
a part of a vector containing mCherry as a reporter protein and a representation of the 
gene of interest [91]. 
The advantage of developing a cell line containing the Tet-On 3G system is that it 
has the ability to be able to induce the cells or embryos at any stage of 
development or growth [93]. This allows the gene to be switched on or off for any 
duration at any time point during embryonic development and can provide insight 
into how the gene functions at the different stages of development or at what time 
point the gene is essential or detrimental. This is critical for pluripotency studies 
as the development of pluripotent embryonic stem cells occurs for one brief time 
point during embryo development. Therefore, temporal investigation into gene 
A. 
B. 
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regulation during embryonic development is required to understand when the key 
genes are activated and when they are repressed.  
 Current status of bovine stem cell research 1.8
To date there has been no successful isolation of pluripotent stem cells in bovine 
or any other domestic ungulate [1]. This is because the understanding of how the 
bovine genome functions is still relatively low [95]. There are a number of 
reasons for this. Firstly, there are problems caused by the lack of an in vitro 
culture for the post hatching stages of development (where the development of 
pluripotent ES cells may arise) [1]. This means that the collection of embryos at 
such a stage requires in vivo culture and recovery via the flushing of the uterine 
tract. This in turn limits the number of embryos recovered and creates obstacles 
for certain treatments such as altering culture conditions and media composition. 
Secondly, there are issues in finding specific probes for bovine, such as primers 
and antibodies, because bovine work is not conducted on such a large scale as 
human or mouse [1]. Our lack of knowledge of the mechanics of pluripotency 
means we cannot yet produce the ideal conditions which could encourage the 
production bovine stem cells. The lack of stem cells slows our knowledge of the 
functioning of genes in the bovine system, creating an endless loop of hurdles for 
this field of research. Progress is currently slow, but there have been many 
advances in the 20 years of research in this field.  
 
This research began with the development of an in vitro fertilisation (IVF) 
protocol to produce large quantities of early bovine embryos. The attempts to 
isolate ES cell cultures from these embryos then quickly began [96]. The culture 
of cell lines derived from the embryos ICMs were more successful in the later 
stages after hatching [97]. Many of the protocols employed within the mouse or 
human species were applied to attempt to produce a similar pluripotent state, 
including LIF supplementation, serum and feeders. Similar to human ES cell 
culture, LIF supplementation did not stimulate pluripotency [98,99]. In the genetic 
analysis of these cells cultures it was found that OCT4 was expressed but there 
was a down-regulation in SOX2 and NANOG after few passages, although they 
were initially expressed [100]. Also many of the key components for the 
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signalling factors of the murine system were also detectable in these cultures, such 
as, LIF, BMP, and WNT [100].  
 
When bovine ES-like cells were analysed against the stringent pluripotency 
validating experiments, they were able to achieve teratoma formation from the 
epiblast of in vivo embryos at day 14, but not from the day 8 to day 10 stages 
[101]. Although no undifferentiated stem cells were identified in any of the 
tumours produced [101]. They have also achieved a chimera after only brief cell 
culture (passage 3-13) [102], although none of these were successful in populating 
the germ line [102]. Ultimately, the bovine ES cell has shown no naïve 
pluripotency. There is clearly much more to be done in terms of bovine ES cell 
derivation. More of what is already known of the mouse and human model can be 
used to identify a timeframe in which the naïvely pluripotent ES cells are formed 
within the early bovine embryo. This project integrated the knowledge discussed 
to do so. 
 The utility of embryonic stem cells and its potential in 1.9
cattle 
The biomedical and agricultural applications of pluripotent stem cells are vast. To 
date ES cells have only been derived from mouse [4] and more recently, in rat in 
2008 [8]. The derivation of human ES cells has taken a different path in terms of 
research and will only be referred to here as a molecular model, as it is the one 
that most closely resembles the bovine (Bos taurus) model [1]. Since the 
discovery of ES cells in the mouse species in 1981 [4], our understanding of the 
mouse genome and its functioning has increased at an unprecedented rate [103] 
and this is currently in progress with the rat genome. However, the progression 
from mouse to rat was slow, and there have even been difficulties in developing 
ES cells for alternative mouse strains. Regardless, many research teams quickly 
began attempting to develop these cells in a variety of agricultural species such as 
goat [104], horse [105], pig [106-108], sheep [107], and cattle [96]. 
 
The reason for this interest is because the stem cell can be used as a scientific tool. 
For example, its use in the development of genetically modified mouse lines [103]. 
The first step of which is to isolate a clonal population of ES cells which contain 
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the desired mutation. The desired mutation is introduced by transfecting the cells 
with a DNA vector sequence. The cell population is then enriched via antibiotic 
selection, as the cells are also transfected with an antibiotic resistant gene. These 
cells are then used to generate chimeras which are whole animals comprised of 
two different sets of genomes, via the injection of the ES cell into a 
pre-implantation embryo. The embryo is then transferred into a foster mouse and 
is carried to full term. The ES cell then incorporates into the adult animal, if by 
chance it produces the population of gametes, then the next generation will 
contain the desired genotype. When these are mated with one another they 
produce a breeding line of mouse which contains the desired genetic 
modifications. This is the technique used to create “knock-in”, “knock-out” or 
“knock-down” lines, where a gene is added, removed, or down-regulated within 
the system. This allows understanding of the function of the gene within the 
organism [103]. The ability for the ES cell to be capable of forming a chimera is 
one of the criteria of the naïve pluripotent stem cell. There have been no such ES 
cells identified in the bovine species [1].  
 
The lack of bovine stem cells has become a barrier against our understanding of 
the bovine genome and is exacerbated by the fact that the bovine generation time 
(approximately 4-6 years [109]) is much longer than that of a mouse (eight to nine 
weeks [110]). Therefore the development of transgenic animals in bovine, 
although achievable, is incredibly challenging, costly and time-consuming to 
understand the function of just one gene. Once bovine stem cells are derived, the 
use of these cells as tools will allow the analysis of genes, which will rapidly 
increase our knowledge of how the bovine genome functions. This will give 
relevance and understanding to the genotyping that dairy and beef farmers are 
already conducting on their herds. In addition, this will culminate in gene 
targeting as it will be applied to enhance the genetic quality of New Zealand’s 
national herd. Ultimately it will increase the productivity of New Zealand’s 
largest industry, the dairy industry. This is the goal of the reproductive 
technologies team at AgResearch; to identify and isolate naive pluripotent stem 
cell in the bovine species. This is just one of the many applications for bovine ES 
cells, more of which will be discussed in section 1.10.  
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 Research rationale and objectives 1.10
The research conducted in accordance with this thesis was an incremental step 
towards the derivation of naïve pluripotent stem cells in bovine. There are a 
number of applications for these cells once they have finally been harvested 
successfully. The bovine system shows higher similarity to the human system than 
the mouse [1] and therefore understanding of the bovine system can give insight 
into how these mechanisms are evolutionarily conserved and ultimately 
comprehension into the human system [1] in which many research experiments 
are unethical.  
 
Because the stem cell can be used to engineer the genome of the bovine, giving 
rise to genetically modified animals in just one generation, there will also be many 
applications available with the use of genetic modification [1]. One opportunity 
for bovine would be the idea that they could be used as bioreactors to produce 
biopharmaceutical proteins [1]. The stem cell population could be modified to 
overexpress a specific gene, producing a desired protein in large quantities. This 
protein could be harvested in their milk and therefore be produced in bulk without 
harming the animals in any way. Similar projects to this have already been 
conducted, such as the recent study which produced Daisy, a cow that produces 
milk that does not contain the common allergen β-lactoglobulin [111]. This cow 
contains an RNAi knock-down which down-regulates β-lactoglobulin, a protein 
that is a major contributor [112] to the 2% of the populations milk allergies [113]. 
Without the availability of bovine stem cells this project took six years. With the 
availability of stem cells many steps such as creating a stable cell line and NT 
cloning can be avoided and the desired cow can be produced much faster.  
 
Another possibility is the use of these animals for human disease modelling, as 
there are many shortcomings for rodents in this function. The much larger size of 
bovine better resembles the human body and modifications to its genome can 
produce a more similar disease model than is achievable by the mouse, giving us a 
better picture of how the disease functions [1]. Also with slight modifications to 
specific genes within the bovine surrounding its immune system, there is the 
possibility of xenotransplatation, which is where bovine could be used as organ 
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donors for humans as long as they have been altered to become 
immunocompatible [1]. They will also make the production of “knock-out” and 
“knock-in” animals much quicker to produce by allowing germline chimera 
formation, which will result in the understanding of the function of a gene in the 
bovine system to be uncovered in a much shorter timeframe. This will culminate 
in a rapid increase in knowledge of the functioning of the bovine system, which 
will mean that genotyping results of elite animals will be better understood.  
 
Most importantly from an agricultural perspective, the isolation of bovine ES cells 
will improve the way animals are selected for breeding. The conventional 
technique was to phenotype the progeny of an animal [114]. This would take six 
years for the course of two generations in bovine, ultimately delaying genetic gain. 
With improvements in DNA sequencing, the genotyping of offspring is now 
possible, although still relatively new, it will allow the selection of embryos that 
have high genetic quality during the IVF procedure, shortening the selection time 
to just one week. Since in vitro procedure (IVP) has a low chance that each 
embryo will survive until calving, the use of ES cells will be of great benefit. If an 
embryo is identified to have desirable genetics, it could be harvested for ES cell 
culture. ES cells are able to generate multiple embryos with the desirable DNA 
through chimera generation. This will rapidly increase the speed of genetic gain in 
the bovine species and has the potential to increase milk yield, decrease disease, 
increase meat quality and decrease environmental impacts of farming, overall 
increasing productivity for the dairy industry.  
 
The overexpression of NANOG was hypothesised to have an effect on related 
pluripotency factors as it has shown this in a number of other models such as 
mouse, pig and human [18,33,115]. Understanding the effects of NANOG 
overexpression in the bovine system was the first objective for this research. To 
investigate this, eight pluripotency-related genes were studied. A series of genes 
that collaborate to produce pluripotency were investigated along with markers of 
the hypoblast. This was to see if there is a decrease in the size of the hypoblast as 
opposed to the epiblast which is identified by NANOG expression [31]. 
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One interesting NANOG target is itself. NANOG can bind to its own promotor 
and either stimulate or supress expression [20]. Therefore, analysis of 
endogenously expressed NANOG versus ectopic NANOG was conducted. Also an 
investigation into the core pluripotency network, OCT4 and SOX2 was performed 
to see if overexpression of NANOG stimulated this network. One of the iPS cell 
factors was also evaluated, Krupple-like factor 4 (KLF4). Klf4 binds directly to 
the promotor region of Nanog [116] and is one of the four factors required in the 
dedifferentiation of cells used in iPS cell generation. It was theorised that the 
increase in NANOG expression would increase the expression of KLF4. FGF4 is 
another gene of interest, in recent 2i studies in bovine, both NANOG and FGF4 
were up-regulated when embryos were cultured in 2i media [37]. The link 
between NANOG and FGF4 is intimate and it was expected that the 
overexpression of NANOG would result in the up-regulation of FGF4.  
 
Consistently in mouse, Nanog has been shown to supress hypoblast markers [31]. 
The hypoblast can be identified by SRY (Sex Determining Region Y)-Box 17 
(Sox17) and platelet-derived growth factor receptor, alpha polypeptide (Pdgfrα) 
[117-119]. Sox17 is a marker for differentiation and directly interacts with the 
pluripotency network as overexpression of Sox17 directs cells into differentiation. 
[117].  It was previously found that SOX17 was significantly down-regulated with 
the use of the 2i treatment in bovine, which also resulted in an up-regulation of 
NANOG [37]. This is likely because Nanog and Sox17 compete for the same 
binding locations [117]. PDGRFα is also a marker for the hypoblast and is 
essential for the proliferation of the hypoblast lineage [118]. This was also 
down-regulated during 2i treatment in bovine [37]. Suppressor of cytokine 
signalling 3 (Socs3) is also a differentiation marker that negatively regulates the 
LIF pathway [120]. It is down-regulated by Nanog and results in an enhanced LIF 
signal transduction. Therefore, with the overexpression of NANOG it was 
expected to result in a decrease in SOCS3 expression. 
 
It was also theorised the inactivation and reactivation of the X-chromosome 
would occur in all mammalian females. Investigation of bovine ES cells and the 
analysis of their X-chromosomes reactivation may illuminate a time point in 
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which ES cells may be targeted for collection in bovine. Based on research 
conducted in the mouse model, showing Nanog’s role in down-regulating Xist, it 
was hypothesised that overexpression in NANOG via the Tet-on 3G system would 
cause a down-regulation in XIST levels. It was theorised that this would result in 
either an increased duration of the double X-chromosome active signal and/or it 
would more completely remove the XIST clouds surrounding the inactive 
X-chromosome. Investigation of the effects of increased NANOG on XIST 
expression was the second objective of this research.  
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 Materials and Methods Chapter 2:
 Materials 2.1
2.1.1 Commercial kits 
All reagents within the commercial kit were used as stated by the protocol 
provided by the manufacturer. Table 1 gives information regarding suppliers.   
Table 1: Kits used for experiments in accordance with the work conducted in this 
thesis. 
Kit Method Source 
E.Z.N.A® kit Gel elution (2.2.11.1.5) E.Z.N.A OMEGA, bio-tek, 
Thermo Fisher Scientific, 
(USA) 
RNAGEM 
TM
 Tissue PLUS kit RNAGEM Tissue Plus 
(2.2.11.1.5) 
ZyGEM, #RTP0500, (New 
Zealand) 
 
2.1.2 Specific equipment and instruments 
All equipment and instruments used for the purposes of this research (Table 2). 
Table 2: Equipment and instruments used for the purposes of this research. 
Equipment Method Make and Manufacturer 
AMG Evos microscope Preparation of cells (2.2.5) AMG Evos, Advanced 
microscopy group, Millenium 
Science, (Australia) 
Autoclave Sterilisation of plastic and 
glassware (Various) 
Tuttanauer autoclave, 
Tuttanauer, (USA) 
Bench centrifuge Molecular analysis (Various) Mini spin, Eppendorf 
(Germany) 
Cell culture centrifuge Tissue culture (Various) Biofage Primo Centrifuge, 
Heraeus, (Germany) 
Cell culture laminar flow Tissue culture (2.2.4) Hera guard, Heraeus, 
(Germany) 
Cell culture incubator Tissue culture (2.2.4) Series II water jacketed CO2 
incubator, Therma Forma, 
Thermo Scientific, (USA) 
Cell microscope Cell counting (2.2.4.4) Nikon TMS, Nikon (Japan) 
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Counter Cell counting (2.2.4.4) BSI ISO9001, Up Green 
Counters, (Taiwan) 
Deep freezer (-80° C) Sample storage Forma 900 series, Thermo 
Fisher Scientific Inc, (USA) 
Electro cell manipulator Cell Fusion (2.2.6.5.2) BTX ECM 200, 
Biotechnologies and 
Experimental Research Inc, 
(CA, USA) 
Electrophoresis power 
supply 
Gel electrophoresis (2.2.13) Power station 300, Labnet 
international Inc, (NJ, USA) 
Electrophoresis unit Gel electrophoresis (2.2.13) Sub-Cell ® GT, BIO-RAD, 
(CA,USA) 
Embryology incubator Embryo culture (2.2.6.6) Contherm biocell 1000 
incubator, 38° C, Contherm, 
(New Zealand) 
Embryology Laminar Flow Embryo generation ( 2.2.6) Model CF 43/40, Gelman 
Sciences, (Australia) 
Embryology mini centrifuge Embryo Culture (Various) Spectrafuge mini C1301, 
Labnet International INC., NJ 
(USA) 
Embryology vortex Enucleation (2.2.6.4) SM1 minishaker IKA ®, 
(Germany) 
Enucleation pipette Enucleation (2.2.6.4) 24 µm diameter, blunt cut 
open end, House made 
Freezer (-20° C) Sample storage Chest freezer, Fisher and 
Paykel (New Zealand) 
Gel doc Gel electrophoresis (2.2.13) Gel doc 2000, BIORAD 
(USA) 
Hand pipettes Various 1 mL, 200 µL, 20 µL, 10 µL, 
2µL, Eppendorf (Germany), 
Gilson (Switzerland) 
Heating block RNAGEM (2.2.7) Accublock™ Digital Dry 
Bath, Labnet International 
Inc, (NJ, USA) 
Haemocytometer Cell counting (2.2.4.4) Bürker Counting Chamber, 
Neubauer, Weber, (UK) 
Ice machine Molecular analysis (Various) Hoshizaki Cube Star FM-
120D, Hoshizaki, (Japan) 
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Liquid nitrogen tank Sample storage Chart MVE Biological 
systems (USA) 
LightCycler mRNA qPCR  (2.2.11) LightCycler 2.0, Roche, 
(Germany) 
LightCycler carousel 
centrifuge 
mRNA qPCR (2.2.11) LC Carousel Centrifuge 2.0, 
Roche, (Germany) 
Micromanipulation 
microscope  
Enucleation (2.2.6.4) MO-188, Nikon Narishige, 
(Japan) 
Microwave oven Gel electrophoresis (2.2.13) The time saver MX145, 
Samsung, (China) 
Milli-Q water production 
unit 
Various Purelab Ultra Elga Reservoir 
75 L, Milipore H2O-
production unit Milli-Q plus, 
Bio Lab, (USA) 
Mr Frosty Freezing cells (2.2.4.3) Cryo 1° C Freezing container, 
Nalgen, Thermo Scientific, 
(USA) 
NanoDrop 
spectrophotometer 
Gel elution (2.2.11.1.5) Nanodrop 1000, Thermo 
Scientific (USA) 
Olympus fluorescent 
microscope 
Photography of 
immunocytochemistry (Section 
2.2.14.1) 
Olympus BX50, Olympus 
(Japan) 
PCR machine End point PCR (2.2.12) Master cycler gradient, 
Eppendorf, (Germany) 
Scale Gel electrophoresis (2.2.13) Mettler AT250, Mettler-
Toledo International Inc, 
(Switzerland) 
Separation needle Enucleation (2.2.6.4) 100-150 µm diameter, blunt 
closed ended, House made 
Suction system for cells Cell culture (2.2.4) Air Cadet, Thermo Scientific, 
(USA) 
Vacuum Sourcing oocytes (2.2.6.2) IVF Ultra Quiet VMAR-
5100, Cook veterinary 
products, (Switzerland) 
Vortex RNAGEM (2.2.7) Grant-bio, Biolab, Thermo 
Scientific, (USA) 
Water bath Cell culture (2.2.4) GD100, Grant, Global 
Sciences, (New Zealand) 
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2.1.3 Plastic and glass ware 
All plasticware was purchased clean and sterile. All glassware was autoclaved at 
121° C for 15-20 minutes time at high pressure. A detailed list of all plastic and 
glassware used can be seen in Table 3. 
Table 3: Detailed list of plastic and glassware used for the purposes of this research. 
Item Method Make and Manufacturer 
15 mL Conical tube Various 15 mL Conical tube, Corning 
® Centristar ™ (USA) 
18 gauge needle Sourcing oocytes (2.2.6.2) BD PrecisionGlide ™ Needle, 
Sigma Aldrich (Switzerland) 
96 well Conical plate Immunocytochemistry  
(2.2.14) 
TC Microwell 96U W/WD 
NUNCLON D, Thermo 
Scientific, (Denmark) 
Circular coverslips Immunocytochemistry (2.2.14) 10 mm Coverglass No. 1, Pro 
Sci Tech, (Australia) 
Cryovials Freezing cells (2.2.4.3) Cryotube ™ Vials, Thermo 
Scientific, (Denmark) 
Filter paper Immunocytochemistry (2.2.14) 150 mm diameter filter paper, 
Whatman Internation Ltd, 
(UK) 
Gilmont ® Micrometer 
syringe 
Enucleation (2.2.6.4) 0.2 mL Gilmont, Cole-Parmer 
Instruments, (IL USA) 
Gridded dish Sourcing oocytes (2.2.6.2) House made, Petri dish with an 
etched in 1 cm grid 
LightCycler Capillaries mRNA qPCR (2.2.11) LightCycler Capillaries, 
Roche, (Germany) 
Microcentrifuge tube Various 0.6 mL, 1.5 mL Graduated 
microcentrifuge with flat top 
cap, Quality Scientific 
Plastics, (USA) 
Modular incubation 
chamber 
Embryo culture (2.2.6.6) Modular incubation chamber, 
QNA International Pty Ltd., 
Australia 
Mouth pipette Embryo culture (2.2.6.6) House made, Tubing with 
mouth piece, filter and puller 
Pasteur pipette 
Parafilm Immunocytochemistry (2.2.14) Parafilm, Bemis flexible 
packaging, (WI, USA) 
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Pasteur pipettes Various Disposable glass Pasteur 
pipettes D810, Poulten & Graf 
(UK) 
PCR tube End point PCR (2.2.12) 200 µL Snapstrip II PCR 
tubes, Scientific Specialties 
Inc, (USA) 
Petri dish Embryo culture (2.2.6) 3 cm, 6 cm, 9 cm Easy grip 
Petri dish, Falcon, (NY,USA) 
Thermos  Sourcing oocytes (2.2.6.2) Nippon, (Japan) 
Tissue culture dish Cell culture (2.2.4) 3 cm, 6 cm, 9 cm, Easy grip 
Tissue culture dish, Falcon 
(NY, USA) 
Vacucap filter unit Solution preparation Vacucap® Filter Unit w/0.2 
µm Supor® Membrane, Pall 
Corporation, (New Zealand) 
Volumetric flask Various Various, Schott Duran, 
(Germany) 
 
2.1.4 Computer software and outsourced services 
A series of computer software was used for the purposes of this research; a 
detailed list can be seen in Table 4. This table also contains outsourced services 
such as primer synthesis. 
Table 4: Computer software and outsourced services. 
Software Method Manufacturer 
Excel Graph formation and 
statistical analysis 
Microsoft, (USA) 
Geneious Bioinformatics (2.2.9) Biomatters Ltd, (New 
Zealand) 
ImageJ Photography of 
immunocytochemistry 
samples (2.2.14.1) 
National Institute of Health, 
(USA) 
LightCycler software qPCR (2.2.11) 4.1.1.21, LightCycler, Roche, 
(Germany) 
NanoDrop software Gel elution (2.2.11.1.5) NanogDrop 1000 3.8.1, 
ThermoScientific, (USA) 
Nucleotide search Primer design (2.2.9) NCBI, (USA) 
Pick primers Primer design (2.2.9) NCBI, (USA) 
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Primer synthesis Primer design (2.2.9) Integrated DNA technologies 
IDT, (USA) 
Quantity one software Gel electrophoresis (2.2.13) Quantity one 4.4.0, BIORAD, 
(USA) 
Spot Basic Software Photography of 
immunocytochemistry 
samples (2.2.14.1) 
Spot imaging solutions, 
(USA) 
Spot RT3 camera Photography of 
immunocytochemistry  
samples (2.2.14.1) 
Spot imaging solutions, 
(USA) 
 
2.1.5 Reagents and media for tissue culture 
All solutions (Table 5) were prepared using Milli-Q water sourced from the Milli-
Q water production unit. Solutions containing non-sterile components were 
filtered using Vacucap filter units. Solutions with “house made” were prepared 
within AgResearch facilities.  
Table 5: Reagents used for tissue culture. 
Common Name Make and Manufacturer Composition 
1 x PBS House made Phosphate buffered saline 
Cell culture media DMEM/F12+GlutaMAX I 
1x , GIBCO, Life 
Technologies, (USA) 
2.438 g/L Sodium Bicarbonate, 
Sodium Pyruvate 
Cryoprotectant House made 80% FCS, 20% DMSO 
DMSO Sigma Aldrich, (Switzerland) Dimethyl sulfoxide 
Doxycycline Sigma Aldrich, (Switzerland) Stock with 2 mg/mL 
Fetal bovine serum (FBS) Moregate, (Australia) - 
Fetal calf serum (FCS) GIBCO,  Life Technologies, 
(USA) 
- 
Gelatin  Sigman Aldrich, 
(Switzerland) 
0.1% in dsMilliQ 
Hygromycin Hygromycin B #10687-010, 
Life Technologies, (USA) 
Maintenance level  200mg/mL 
Low serum media House made 0.5% FCS, 99.5% cell culture 
media 
TrypLE TrypLE Express, GIBCO, 
Life Technologies, (Denmark) 
- 
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2.1.6 Reagents for nuclear transfer and embryo culture 
A list of reagents used for nuclear transfer can be found in Table 6. All reagents 
with the make and manufacturer stated as “house made” were prepared within 
AgResearch facilities.  
Table 6: List of reagents used for nuclear transfer and embryo culture. 
Common name Make and 
manufacturer 
Composition 
Aspiration media House made H199 medium + 925 IU/mL Heparin, CP 
Pharmaceuticals, (UK) + 2% (w/v) foetal calf 
serum, Life Technologies, (USA) 
B199 House made Bicarbonate-buffered medium M199 with 25 
mM NaHCO3, 0.2 mM Pyruvate and 0.086 
mM Kanamycin monosulfate 
Bovine Serum Albumin 
(BSA) 
Sigma Aldrich, 
(Switzerland) 
- 
D-MAP House made 6-dimethylaminopurine, Sigma Aldrich 
(Switzerland), 74.62 mg/mL in DMSO 
ESOF (Early synthetic 
oviduct fluid) 
House made 107.7 mM NaCl, 7.15 mM KCl, 0.30 mM 
KH2PO4, 25 mM NaHCO3, 0.33mM 
C3H3O3Na, 1.71 mM CaCl2:2H20, 0.15 mM 
C6H12O6, 3.32 mM C3H5O3Na, 0.04 mM 
C18H36N4O11H2SO4, and 0.081 g/L Non 
Essential Amino Acid, 1 mM Gluta-Max, and 
8 mg/mL BSA. 
ESOF –Ca + 10% FCS House made - 
H199 House made Hepes-buffered M119 with 15mM Hepes, 5 
mM NaHCO3, and 0.086 mM kanamycin 
monosulfate 
H199 + 3 mg/mL BSA House made H199 + 3 mg/mL BSA 
H199 + 0.5% FCS House made H199 + 0.5% FCS 
H199 + 10% FCS House made H199 + 10% FCS 
HSOF (Hepes buffered 
synthetic oviduct fluid) 
House made 107.7 mM NaCl, 7.15 mM KCl, 0.3 mM 
KH2PO4, 5 mM NaHCO3, 3.32 mM sodium 
lactate, 0.069 mM kanamycin monosulfate, 
20 mM Hepes, 0.33 mM pyruvate, 1.71 mM 
CaCl2.2H2O, 3 mg/mL fatty-acid free bovine 
albumin 
HSOF -Ca + 10% FCS House made - 
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Hyaluronidase House made Hyaluronidase, Sigma Aldrich (Switzerland), 
0.1% in H199 -BSA. 
Hypoosmolar fusion 
buffer 
House made 165 mM mannitol, 50 µM CaCl2, 100 µM 
MgCl2, 500 µM Hepes, 0.05% bovine 
albumin [ABIVP, ICP], pH 7.3 
Ionomycin House made Ionomycin Ca salt, Sigma Aldrich, 
(Switzerland), 1 mg in 268 µL DMSO 
IVM media House made B199 with 10 µg/mL ovine follicle 
stimulating hormone, Ovagen; Immuno-
Chemical Products, (New Zealand), 1 µg/mL 
ovine lutenizing hormone, 1 µg/mL 17-β-
estradiol, 0.1 mM cysteamine 
Lectin House made Phytohaemagglutinin PHA-P, Sigma Aldrich 
(Switzerland), 2 mg/mL in H199 + 3 mg/mL 
BSA 
LSOF (Late synthetic 
oviduct fluid) 
House made 107.7 mM NaCl, 3.99 mM KCl, 1.20 mM 
KH2PO4, 25 mM NaHCO3, 0.33 mM 
C3H3O3Na, 1.71 mM CaCl2:2H20, 0.49 mM 
MgCl2:6H2O, 3.32 mM C3H5O3Na, 0.04 
mM C18H36N4O11H2SO4, 1.5 mM 
C6H12O6, 1 mM DNP (2-, 4-dinitrophenol) 
and 0.081 g/L Non Essential Amino Acid, 1 
mM Gluta-Max, 0.22 g/L BM Essential 
Amino Acid and 8 mg/mL BSA. 
Pronase House made Protease, Sigma Aldrich, (Switzerland), 0.5% 
in HSOF + Ca + Mg + 1 mg/mL PVA 
M199 House made Medium 199 with L- glutamine, Earle’s salts, 
Life Technologies, (USA) 
Mineral oil Sigma Aldrich, 
(Switzerland) 
Sterile-filtered, BioXtra 
 
2.1.7 Reagents for molecular biology 
A comprehensive list of reagents used for molecular biology can be found in 
Table 7.  
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Table 7: List of reagents used for all molecular biology protocols. 
Reagent Method Manufacturer 
1 Kb ladder Gel electrophoresis (2.2.13) 1 Kb Plus DNA ladder, 
Invitrogen, Life Technologies, 
(USA) 
5 x RT-buffer cDNA synthesis (2.2.7.4) 5 x First Strand buffer, 
Invitrogen, Life Technologies, 
(USA) 
dNTP cDNA synthesis (2.2.7.4) 10 mM diluted from 100 mM 
dNTP Set, Invitrogen, Life 
Technologies (USA) 
Loading dye Gel electrophoresis (2.2.13) House made, 15 mL 30 % 
glycerol in H20, 35 mL H20 + 
0.5 g 1% Orange dye, Sigma 
(Switzerland) 
Lysis Buffer DNA extraction (2.2.8) Tris pH8 100 mM, EDTA 1 
mM, Tween-20 0.5% (v/v), 
TX-100 0.5% (v/v), House 
made 
MgCl cDNA synthesis (2.2.7.3) 25 mM stock solution, Roch 
diagnostics, (Germany) 
Proteinase K DNA extraction (2.2.8) Proteinase K, Sigma Aldrich, 
(Switzerland) 
Random Hexamer primers cDNA synthesis (2.2.7.4) 5 nmoles, Applied 
Biosystems, Roche (Germany) 
RNAse out cDNA synthesis (2.2.7.4) RNAse OUT ™ Recombinant 
Ribonucleas Inhibitor 5,000 
U, Invitrogen, Life 
Technologies, (USA) 
Superscript III cDNA synthesis (2.2.7.4) Superscript ® III, Reverse 
Transcriptase, Invitrogen, Life 
Technologies, (USA) 
SYBR safe Gel electrophoresis (2.2.13) SYBR® Safe DNA Gel stain, 
Life Technologies, (USA) 
Takara qPCR (2.2.11) SYBR Premix Taq II (Tli 
RNAse H Plus), Norrie 
Biotech, (New Zealand) 
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2.1.8 Reagents used in immunocytochemistry 
Reagents used for the immunocytochemistry protocol are listed in Table 8. All 
reagents with the make and manufacturer stated as “house made” were prepared 
within AgResearch facilities. 
Table 8: Table of reagents used in immunocytochemistry. 
Reagent Details Make and Manufacturer 
Donkey Serum 5% work concentration in 
PBS 
Sigma Aldrich, (Switzerland) 
Goat Serum 5% work concentration in 
PBS 
Life Technologies, (USA) 
Hoechst stain (H33342) 5 µg/mL working 
concentration, Bis-Benzimide 
in 1 mg/mL Mili-Q water 
Sigma Aldrich, (Switzerland) 
Mounting media - ProLong Gold Antifade or 
ProLong Diamond Antifade 
(Dependent on availability), 
Life Technologies, (USA)  
NH4Cl 50 mM Sigma Aldrich, (Switzerland) 
Paraformaldehyde (PFA) 4% depolymerised (w/v) 
PFA, 4% (w/v) sucrose, 1 M 
NaOH in PBS with phenol 
red indicator 
Sigma Aldrich, (Switzerland) 
PBS-PVA 5% 1 mg/mL PVA in PBS House made 
Triton X-100 - Sigma Aldrich, (Switzerland) 
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2.1.9 Primary and secondary antibodies used in 
immunofluorescence 
Primary and secondary antibodies used in immunocytochemistry are listed in 
Table 9. 
Table 9: Details of primary and secondary antibodies used for 
immunocytochemistry. 
Antibody Dilution Cloniality Species Manufacturer 
Primary     
H3K27me3 1:10,000 Polyclonal Rabbit Millipore 
#NM_003493 
NANOG 1:100 Monoclonal Mouse eBiosciences (USA) 
#14-5768 
SOX2 1:30 Polyclonal Goat R & D Systems 
(USA) #AF2018 
Secondary     
Donkey anti 
Mouse Alexa 
Fluor® 488 
(Green) 
1:1000 - - Invitrogen (USA) 
#A21202 
Donkey anti 
Goat Alexa 
Fluor® 568 
(Red) 
1:1000 - - Invitrogen (USA) 
#A11057 
Donkey anti 
Rabbit Alexa 
Fluor® 488 
(Green) 
1:1000 - - Invitrogen (USA) 
#A21206 
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2.1.10 Frequently used reagents 
Commonly used reagents used throughout the range of protocols can be found in 
Table 10. All reagents with the make and manufacturer stated as “house made” 
were prepared within AgResearch facilities. 
Table 10: List of commonly used reagents. 
Reagent Details Manufacturer 
50 x TAE buffer 241.2 g 2M Tris, 15.01 mL 250 
mM Glacial acetic acid, 18.61 g 50 
mM EDTA 
House made 
DEPC 0.1% (v/v) diethyl procarbonate in 
Milli-Q water. Mixed overnight 
and autoclaved 
House made 
dH2O - Distilled water, Nalgene 
Ethanol 70% diluted in DEPC Fisher Chemicals,  
Milli-Q water 18.2 MΩ From Milli-Q reservoir 
PBS 8.4 mM disodium hydrogen 
orthophosphate 2-hydrate, 1.9 mM 
sodium dihydrogen 
orthophosphate 1-hydrate, and 150 
mM sodium chloride in MQ-H2O 
House made 
TAE buffer 1 x TAE diluted from 50 x stock House made 
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2.1.11 Primers 
A series of primers was used for both qPCR and PCR analysis of samples. The 
sequence and additional information about these primers can be seen in Table 11. 
Table 11: List of primers describes sequences, melting peak and amplicon size.  
Gene Sequence (5’-3’) qPCR 
Melting 
peak (°C) 
Amplicon 
size (bp) 
18S F:GACTCATTGGCCCTGTAATTGGAATGAGTC 
R: GCTGCTGGCACCAGACTTG 
80 87 
DDX3Y F: GGACGTGTAGGAAACCTTGG 
R: GCCAGAACTGCTACTTTGTCG 
81 225 
Ectopic 
NANOG 
F: CACGGGGACGTGGTTTTCCTTT 
R: CTGCAGGGACACGTAGGATTCCTC 
88 166 
Endogenous 
NANOG 
F: TCACACCCGGAGATCTTCAC 
R: TCCATGGAGGAGGGAAGAGG 
84 274 
FGF4 F: TACGGCTCGCCTTTCTTCAC 
R: TTCTTGGCCTTGCCGTTCTT 
89 131 
GAPDH F: GGCGTGAACCACGAGAAGTATAA 
R: CCCTCCACGATGCCAAAGT 
84 118 
KLF4 F: TCCCACCGCTCCATTAC 
R: ATGAGAACTCTTCGTGTAGG 
88 158 
OCT4 F: GGTTCTCTTTGGAAAGGTGTTC 
R: TGGCGACGGTTGCAAAACCA 
89 333 
PDGFRα F; CCCCGACGTGGAAATCAGAA 
R: CATCTGGGTCTGGCACGTAG 
88 179 
SOCS3 F: CCAGCCTGCGCCTCAAGACC 
R: AAAGTGGCGCTGGTCCGAGC 
91 185 
SOX2 F: CTATGACCAGCTCGCAGA 
R: GGAAGAAGAGGTAACCACG 
90 152 
SOX17 F: ATGCTGGGCAAGTCGTGG 
R: CTTTAGCCGCTTCACCTGCTT 
93 147 
USP9Y F: GCCAGATGACCAAGAAGCCCCA 
R: GGACTGTAAGGCCTAATAGCCTGGT 
- 285 
XIST F: AGCATTGCTTAGCATGGCTC 
R: TGGCTGTGACCGATTCTACC 
85 466 
ZRSR2Y F: GTCAGTTGCAACCTGGAACC 
R: GCCATATTCCATTGGGTCAC 
- 158 
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2.1.12 Cell line details 
All cell lines used for the purposes of this project were bovine. Their names and 
cell type details can be seen in Table 12. 
Table 12: Details of all bovine cell lines used for the purposes of this research. 
Cell line 
common 
name 
Cell line full name Cell type Source 
EFC1B Elizabeth Follicular Cells, 
Line 1B 
Follicular isolated from adult 
ovary 
AgResearch 
[121] 
EOG EF5_EF1α_OCT4-GFP Foetal fibroblasts isolated from 
day 45 embryo 
AgResearch 
[122] 
EOG_TET EF5_EF1α_OCT4-
GFP_TET3G_TRE3G 
Foetal fibroblasts isolated from 
day 45 embryo 
AgResearch 
EOG_TET_
NANOG 
EF5_EF1α_OCT4-
GFP_TET3G_TRE3G_NA
NOG 
Foetal fibroblasts isolated from 
day 45 embryo 
AgResearch 
LFC2 Lady Follicular Cell, line 2 Follicular isolated from adult 
ovary 
AgResearch 
[123] 
LJ801 Limousine Jersey 801 Skin fibroblast isolated by ear 
biopsy 
AgResearch 
[124] 
SNAZY SNAZY Skin fibroblast isolated by ear 
biopsy 
AgResearch 
[124] 
 
 Methods 2.2
2.2.1 Ethics statement 
All research was exempt from animal ethics approval as the research conducted 
was on early stage embryo or in vitro culture of cell lines. No approval was 
required from the University of Waikato animal ethics committee or AgResearch 
animal ethics committee. This project had environmental protection agency (EPA) 
approval under the hazardous substances and new organisms (HSNO) act. The 
EPA approval number for this project is GMO05/ARR003. 
2.2.2 Cell culture 
Cell culture is the removal of cells from the organism as a whole and growing of 
these cells in vitro under controlled conditions [125]. The bovine fibroblast cell 
line used for the purposes of this research thesis was named EOG_TET_NANOG. 
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This cell line was derived within AgResearch, New Zealand. The history of the 
cell line is described in section 2.2.3. 
2.2.3 Background information about the cell line 
The EOG_TET_NANOG cell line was prepared prior to the work conducted in 
this thesis. The bovine cell sample was initially taken from the embryo of a 
natural mating of a dairy cow with a high breeding index and a high genetic 
quality sire. The embryo was recovered at day 60 and was originally called 
EF5LG, describing that it was a bovine embryonic fibroblast derived from the 
foetal lung.  
 
This cell line was then transfected with a bovine OCT4- green fluorescent protein 
(GFP) promoter construct and used for NT to determine the expression of OCT4 
within the cloned bovine blastocyst [122]. A transfected clone from this cell line 
was used for NT and a resulting embryo was recovered at day 45. The re-derived 
tissue from this foetus was then used to develop a new foetal fibroblast cell line 
called EOG (Table 9). The OCT4-GFP vector sequenced was silenced over this 
period but is on occasion reactivated unpredictably. Therefore, its GFP signal was 
visualised and recorded during these NT experiments.  
 
The EOG cell line was transfected via Neon-electroporation with the Tet-3G 
system by Clone-tech. This contained the reverse tet transactivator (rtta) which 
drives gene transcription by binding to tetO in the presence of doxycycline. This 
was a minimal promoter sequence which means it was less likely to be silenced. 
This also had a pEF-1α promoter which was linked to a Neomycin resistance 
marker that was derived by a separate SV40 promoter. The clones were then 
selected with Neomycin and tested for inducibility. The best clones were then 
selected and expanded. The cell line was then used for NT. A day 45 embryo was 
recovered and a new cell line was created. This was again tested for inducibility. 
At this stage the cells were named EOG_TET (Table 12). This cell line was often 
used as a control treatment for the EOG_TET_NANOG cell line as it was parental 
and constitutively expressed the Tet-activator but did not contain NANOG 
sequence. 
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The cell line was then transfected again with a vector from GeneArt. The vector 
contained the tetracycline responsive element of the third generation (TRE3G). 
This contained a mCherry reported protein to indicate that the vector was on, 
where the sequence was being transcribed. The sequence also contained 
codon-optimised NANOG sequence which was optimised based on which codon 
was most efficient at transcription and translation for that particular amino acid. 
Therefore, there was a difference between the mRNA sequence of the vector and 
the endogenously expressed NANOG which allowed them to be distinguished. 
The protein sequence was the same for both ectopically and endogenously 
expressed NANOG. The comparison between the codon-optimised and 
endogenous Nanog nucleotide sequences can be seen in section 3.1 along with a 
comparison of the corresponding protein sequences. The pTRE3G-mCherry 
vector also contains an internal ribosomal entry site (IRES), which allows the 
mCherry-NANOG mRNA hybrid sequence to be translated, but then are 
transcribed separately to form separate proteins (Figure 7). A plasmid map for this 
sequence can be seen in Figure 8. The cells were also simultaneously transfected 
with a Hygromycin resistant vector and were selected based on mCherry 
expression and Hygromycin resistance by SV40 promotor.  
 
Figure 8: Plasmid map for pTRE3G-mCherry vector. The location for IRES, 
ampicillin (AmpR), SV40 promotor and fused tetracycline responsive element-mCherry 
reporter protein-NANOG gene are depicted in the 5618 bp vector.  
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The line was then again rejuvenated via NT. Only those embryos with mCherry 
expression at day 7 were selected for embryonic transfer. A day 45 embryo was 
then recovered and the cells were harvested. Doxycycline was added to the cells 
and it was found that around 33% of them were positive for mCherry 
(Unpublished data). At this point, a number of NT runs were conducted and qPCR 
analysis of embryos was used to analyse NANOG expression. The results for these 
NT runs can be seen in results section 3.2. A diagram of the work conducted up 
until this point can be seen in Figure 9. This cell line was then given the common 
name EOG_TET_NANOG (Table 12). 
 
Figure 9: History of EOG_TET_NANOG cell line. Details of parental cell lines Table 
12. Contains image of day 45 embryo and each step of the derivation of the 
EOG_TET_NANOG cell line. Diagram from Bjӧrn Oback  (unpublished). 
After these initial NT runs, it was concluded that the cell line did not contain a 
high enough concentration of mCherry positive cells. It was then sorted for the 
mCherry signal by a fluorescence-activated cell sorter (FACS) at University of 
Auckland, New Zealand. The percentage of cells expressing mCherry after sorting 
was 98% (Unpublished data). The cells were then expanded and frozen down to 
be analysed via immunocytochemistry (ICC) and qPCR for NANOG expression. 
2.2.4 Routine cell culture protocols 
All mammalian cell culture work was conducted with in the cell culture laminar 
flow using aseptic technique. Cells were grown in the cell culture incubator which 
was kept at 38.5° C, with a gas composition of 5% CO2. 
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2.2.4.1 Thawing cells 
Cryovial tubes containing frozen cells were stored in a liquid Nitrogen storage 
tank in order to preserve them for future use, as they are able to recover from 
cryopreservation and continue to proliferate. To thaw these cells liquid Nitrogen 
was poured into a polystyrene box and a cryovial was quickly removed from the 
storage tank with forceps and placed into the liquid nitrogen. The cryovial was 
then incubated in a 38° C waterbath in order for the cells to thaw. The thawed 
cells were added to a 15 mL conical tube containing pre-warmed cell culture 
media. The tube was then centrifuged using the cell culture centrifuge for 3 
minutes at 1000 rpm at room temperature (RT) to pellet the cells. The supernatant 
was then aspirated using a Pasteur pipette attached to a suction system. The cells 
were then re-suspended in pre-warmed cell culture media, where they were well 
mixed and then transferred into a tissue culture dish. The dishes were labelled 
with the cell line name, date of thawing, the number of cells plated and the 
passage number.  
2.2.4.2 Passaging cells 
Each passage number reflects when cells have outgrown the dish they were 
cultured in and have been transferred into a new dish, giving them more space and 
fresh nutrients to continue proliferation. Before passaging, cells could be 
visualised based on morphology to observe any potential changes as a result of 
induction or culture conditions. Firstly, the cell culture media was aspirated off 
the dish. The cells were then washed with pre-warmed 38° C 1 x PBS. The PBS 
was aspirated and warm trypLE was added to the dish. The dish was then 
incubated for 3-5 minutes in the cell culture incubator, which dislodged the cells 
from the surface of the dish. Large clumps of cells were disrupted by gently 
pipetting the cells up and down. The media containing the cells was transferred to 
a centrifuge tube containing pre-warmed media. The tube was centrifuged for 3-5 
minutes at 1000 rpm at RT. The supernatant was aspirated and the cell pellet was 
loosened by lightly tapping the tube on the bench. The pellet was then diluted in 
the required volume of media and transferred into a new tissue culture dish. The 
culture dish size requirements for seeding density and media volume can be seen 
in Table 13. The cells were then incubated at 38° C until the cells reach a 
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confluency of 70-90%, at which time they must be passaged again or frozen for 
future use.  
Table 13: Seeding density and media requirements for each size of tissue culture 
dish. 
Dish size Seeding density 
(cells) 
Volume of media 
(mL) 
Volume of 
trypLE (mL) 
4 well plate 50,000 0.8 0.2 
35 mm dish 200,000 2 0.5 
60 mm dish 500,000 5 1 
90 mm dish 1,000,000 10 2 
 
2.2.4.3 Freezing cells 
Since these cells are not immortal, and require time and resources to continue 
growth, it was often necessary to freeze the cells, until they are needed again. 
Cells were frozen when they reached 70-90% confluency as this was when the 
cells were at a log phase. Therefore, they could recover quickly after thawing and 
begin proliferation again. The cells were lifted off the tissue culture plate with 
warm trypLE. They were then suspended in pre-warmed media and centrifuged at 
1000 rpm for 3 minutes. A cryoprotectant solution was prepared immediately 
prior to use. The media the cells were frozen in was comprised of 50% 
Cryoprotectant and 50% cell culture media. Once the cells had formed a pellet 
they were then re-suspended in cell culture media. The cryoprotectant was then 
added slowly and the entire solution was mixed to produce homogeneity across 
the sample. The cryovial was labelled with the cell line name, the date of freezing, 
the passage number, the cell count and the technician’s initials. The cells were 
then placed into a Mr Frosty freezing container, which was then placed into a -
80° C freezer. The Mr Frosty controlled the temperature decrease to one degree 
per minute, which is the optimal rate of freezing to keep the cells viable. After a 
24 hour period the cells were transferred into a liquid nitrogen tank for future use.  
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2.2.4.4 Cell counting 
A haemocytometer was used to determine the cell count. A cell count must be 
conducted in a number of different steps as cells must be passaged at densities as 
stated in Table 13, since this is crucial to continue healthy cell growth. A 10 µL 
volume of media containing cells was pipetted onto a haemocytometer, to fill the 
counting area. Under the cell microscope at 10 X objective the cells were counted 
using a 10 - X cell counter on phase contrast. 
              
Figure 10: Haemocytometer diagram. A) An aerial view of the haemocytometer, 
highlighting the counting area, the notch in which the cells are added and the coverslip. B) 
An enlarged view of the counting area. 
The cells in the grids numbered one to four, and the centre grid (Figure 10) were 
counted and the numbers were entered into Equation 1.  
Equation 1: Cell count formula 
 
𝐶𝑒𝑙𝑙 𝑐𝑜𝑢𝑛𝑡
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑠𝑞𝑢𝑎𝑟𝑒𝑠 𝑐𝑜𝑢𝑛𝑡𝑒𝑑
× 𝑉𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑚𝑒𝑑𝑖𝑎 × 10,000
= 𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 
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The count was set up in duplicate as there were two grids on the haemocytometer 
and the results were averaged to obtain an accurate estimation. The cell solution 
could then be diluted to produce the appropriate seeding density. 
2.2.5 Preparation of cells for ICC, RNA extraction and qPCR 
analysis 
Cells were thawed (2.2.4.1) and were passaged at an appropriate seeding density 
into a tissue culture dish containing sterile circular cover slips. To induce the cells 
doxycycline was added to the EOG_TET_NANOG + Dox treatment immediately 
after seeding the cell at a quantity of 1 µL/mL. The cells were incubated for 48 
hours which resulted in a confluency of approximately 80% which is ideal for 
ICC.  
 
After 48 hours, the cells were analysed for confluency and induction. They were 
initially visualised under the AMG EVOS microscope. Once the cells were 80% 
confluent and the EOG_TET_NANOG + Dox treatment showed a strong positive 
mCherry signal then the cells were collected for ICC and RNAGEM. For ICC the 
coverslips were removed and placed into a new 3 cm dish in which the ICC 
protocol was to be carried out (Section 2.2.14). Once they were removed the 
remaining cells were lifted off the plate with TrypLE, they were then washed in 
PBS. A cell count (Section 2.2.4.4) was conducted as the RNAGEM protocol 
(Section 2.2.7) can only process 500,000 cells at a time. If the cell count was 
above 500,000 the excess cells were discarded. The remaining pellet was 
re-suspended in 50 µL of RNAGEM solution. Once the cell line was validated for 
the presence of NANOG expression, it could then be used as a donor cell line for 
nuclear transfer cloning.  
2.2.6 Embryo generation via nuclear transfer 
The production of bovine nuclear transfer embryos was carried out in a physical 
containment level 2 (PC2) embryology laboratory at AgResearch Ltd, Ruakura, 
Hamilton. All plates used in this procedure for IVP were made two hours prior to 
use, in the embryology laminar flow and then were gassed in a humidified 
incubator containing 5% CO2 at 38° C. Plates used for in vitro culture (IVC) were 
made 2 hours prior to use and were stored in humidified modular incubator 
chamber at 38° C with a gas composition of 7% O2, 88% N2 and 5% CO2. 
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Further information about the composition of media, solutions or reagents can be 
found in section 2.1.6. The information for each NT run was recorded on a on a 
fusion record sheet (Appendix 1), these were collected alongside mCherry and 
GFP record sheets (Appendix 2) and embryo grading sheets (Appendix 3). 
2.2.6.1 Cell cycle coordination 
The process of NT has been proven to most successfully generate embryos with 
cells that are in the G0 phase of the cell cycle [126]. To synchronise into the G0 
phase, the cells must be serum starved. The cells were washed three times in 
38° C PBS to remove remaining serum from previous media. A low serum media 
was then used, at 0.5% foetal calf serum and not replenished for the remaining 3-7 
days prior to nuclear transfer. For the fibroblast cells used in these experiments, a 
five day serum starvation was sufficient to synchronise cells. For the duration of 
serum starvation the EOG_TET_NANOG +Dox treatment had the doxycycline 
replenished every 48 hours. 
2.2.6.2 Sourcing oocytes and follicular aspiration (Day-1) 
A population of oocytes primed for NT has been identified for follicular aspiration 
[127]. This population consists of oocytes matured via in vitro maturation until 
they are in metaphase II of meiosis. These are aspirated from follicles within a 
size range defined in Figure 11 [128]. For the purposes of these experiments, 
bovine ovaries (Figure 12) were retrieved from abattoirs in the Waikato region. 
Upon removal from the offal, these were placed into a thermos containing 0.9% 
saline solution warmed to 29.5-30.5° C. They were transported to AgResearch and 
aspiration was conducted no longer than 3 hours after collection. An 18-gauge 
needle under a 48 mm Hg vacuum was used to collect the follicular fluid 
containing oocytes of the appropriately matured follicles as indicated in Figure 11. 
The cumulus–oocyte complexes (COCs) were collected in a 15 mL centrifuge 
flask containing 2 mL 38° C aspiration media so they could be used for in vitro 
maturation. 
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Figure 11: Potential sizes for bovine follicles with red lines indicating follicles prime 
for aspiration. 
 
Figure 12: Bovine ovaries showing varied sizes of follicles and varied stages of 
follicular development. 
2.2.6.3 In vitro maturation (IVM) (Day -1) 
The IVM step allows the oocytes to mature to a state in which they are ready for 
enucleation. The COCs formed a pellet at the bottom of the 15 mL centrifuge tube 
which was removed with a Pasteur pipette and was then expelled into a 9 cm petri 
dish containing aspiration media. The dish was searched using a gridded 9 cm 
dish lid underneath for guidance. Oocytes were selected based on appearance, 
compact COCs, homogeneous ooplasm and a non-atratic cumulus 
oophorus-corona [129]. The selected COCs were then washed through two 
pre-warmed 3 cm dishes of H199 and finally through a 3 cm dish containing B199. 
Using a 10 µL pipette 10 oocytes in 10 µL were taken up and placed into each of 
the 40 µL IVM media drops arranged in three rows of four overlaid with mineral 
oil (Figure 13). These were then placed in an embryology incubator for 18-20 
hours to allow them to mature. 
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Figure 13: Standard culture dish layout. This layout was used for any multi-culture 
period, drop size may vary from 30-40 µL depending on culture requirements. Mineral oil 
overlays the culture drops to retain the heat and gas composition within the dish during 
the time in which the dish is worked on outside the incubator. 
After maturation the cumulus corona were dispersed by the embryology vortex. 
Up to 180 COCs were placed into a 1.5 mL microcentrifuge tube containing 
500 µL of bovine testicular hyaluronidase for two minutes at 2000 rpm. This 
removes the cumulus cells. The tube was then spun down for around three 
seconds with the embryology mini centrifuge in order to collect the oocytes. The 
oocytes were then washed two times in H199 + 10% FCS and then once in 
H199 + 3 mg/mL BSA. Oocytes which have a polar body present were identified; 
these went on to have their zona pellucida (zona) removed via a one-two minute 
incubation in pronase (5 mg / mL in H199). Once the zona begun to dissolve it 
was then washed in H199 + 3 mg/mL BSA. The zona was then dissolved 
completely and the oocytes were allowed to recover their spherical shape for five 
minutes before commencing the enucleation phase.  
2.2.6.4 Oocyte enucleation  
Enucleation is the removal of oocyte DNA to make way for the donor cell genome 
to enter the oocyte and begin embryonic development. For this process, 40 
Culture media drops 
Mineral oil 
4  
 
   t
A
B6C
60 mm dish 
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oocytes were processed at a time. These were collected and incubated in a plate of 
DNA stain (5 µg/mL Hoechst 33342 in H199 + 3 mg/mL BSA). Oocytes were 
then washed briefly in H199 + 3 mg/mL BSA. Once washed the oocytes were 
transferred into a 10 cm petri dish lid containing drops of H199 + 10% FCS 
overlaid with mineral oil. This dish was placed on the warm stage (32° C) of the 
micromanipulation microscope where three axis oil hydraulic hanging joy stick 
micromanipulators along with a 0.2 mL Gilmont ® micrometer syringe were used 
to manipulate the blunt aspiration pipette and the separation needle. The 
enucleation procedure was conducted using 100X total magnification, under 
constant UV light exposure. The aspiration pipette was used to remove the 
metaphase plate of the oocyte.  Once the chromosomes where detected within the 
aspiration needle, the separation needle was used to move the cytoplast away and 
separate it from the karyoplast. The cytoplast was then quickly moved out of the 
UV light.  
2.2.6.5 Nuclear transfer 
The nuclear transfer step is the process that joins the donor cell and the enucleated 
oocyte together, and then fuses them, causing the donor cell’s DNA to enter the 
cytoplast, allowing embryo development to begin.  
2.2.6.5.1 Cell attachment 
Cells prepared in 2.2.6.1 were lifted off their plates with trypLE and were 
re-suspended at 1 x 10 
4
 cell/mL in H199 + 0.5% FCS. This solution was then 
pipetted into 40 µL drops overlaid with mineral oil. From this drop, in groups of 
5-10, the donor cells were removed and added to drop of 10 µg/mL Lectin in 
H199 + 3 mg/mL BSA. The cytoplasts (prepared in 2.2.6.4) were also placed into 
the same drop, five to ten at a time. The donor cells and cytoplasts were pushed 
together with a mouth pipette to form a couplet. The couplets were incubated for 
five minutes, and then transferred into a H199 + 3 mg/mL BSA wash. 
2.2.6.5.2 Cell fusion 
The couplets from step 2.2.6.5.1 were equilibrated in hypoosmolar fusion buffer 
in groups of ten at a time. At RT the couplets were then placed into a custom 
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made fusion chamber which was hooked up to an electro cell manipulator. An 
alternating current field (60-100 V/cm) was applied to the couplets for 5-10 
seconds. This was conducted in order to align the couplets with the donor cell 
either at the top or the bottom of the cytoplast. Fusion was induced with two 
10 µsec direct current pulses (1.5-2.0 kV/cm) immediately followed by an 
alternating current for between 5-10 seconds (60-100 V / cm). The couplets were 
then moved into a dish containing H199 + 3 mg/mL BSA. The couplets were 
visualised to detect potential cell lysis or detachment of the donor and cytoplast. 
These were washed through with HSOF- Ca + 10% FSC and then through two 
40 µL drops of ESOF-Ca. Finally, ten reconstructs per drop in ESOF-Ca + 10% 
FSC were incubated for four hours until activation. The ESOF-Ca + 10% FCS 
plates contained doxycycline for the EOG_TET_NANOG +Dox treatment. 
2.2.6.5.3 Activation 
Activation is the step that stimulates the reconstruct to begin embryonic 
development; it does this by mimicking the process initiated by the sperm during 
fertilisation. This step occurs approximately four hours after fusion. The 
reconstructs were moved into 3 cm dishes containing HSOF + 1mg/mL BSA 30 
minutes prior to fusion, one dish per treatment. The reconstructs were then 
transferred into fresh Ionomycin (1 µL/mL of HSOF + 1 mg/mL) for 4.5 minutes. 
They were then transferred into HSOF + 30 mg/mL BSA for 3 minutes. Then with 
a mouth pipette, each reconstruct was placed into single culture of D-MAP. The 
D-MAP plates contained doxycycline for the EOG_TET_NANOG +Dox 
treatment. The D-MAP plate was laid out to allow single embryo culture (Figure 
14). 
2.2.6.6 Embryo culture 
2.2.6.6.1 Embryo culture 
The reconstructs were then cultured in a media to promote normal embryonic 
development. ESOF is a synthetic oviduct fluid specific for the needs of the 
developing early embryo. This was used to culture the embryos for the initial 
culture period. Once the reconstruct had been activated, they were incubated in 
D-MAP for four hours. During this time the ESOF plates were made, in order to 
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ensure that the doxycycline was fresh and would last as long as possible through 
embryo culture. The ESOF plates were made with a layout (Figure 14) that allows 
single culture of the embryos, to prevent the embryos from joining together and 
forming aggregates. These were placed in a modular-incubation chamber for two 
hours to equilibrate. Each reconstruct was then moved from the D-MAP into a 
HSOF wash dish and then into a single culture ESOF plate, which contained 
doxycycline for the EOG_TET_NANOG +Dox treatment. These plates were 
placed into a modular-incubation chamber, which is a sealed container that was 
gassed with 5% CO2, 7% O2 and 88% N2 at high pressure for 5 minutes. The 
chamber was then sealed and stored in a 38° C incubator until the doxycycline 
needed to be refreshed. 
 
Figure 14: Single embryo culture dish for zona free NT embryos. Contains 3 x 40 µL 
wash drops in which the embryos were washed through before being placed individually 
into the 5 µL  embryo culture drops. 
2.2.6.6.2 Refreshing doxycycline in embryo culture 
Doxycycline only remains active for 48 hrs at the 2 mg/mL concentration required. 
Therefore, it must be refreshed every 48 hours to maintain the induction of the 
pTRE3G-mCherry vector throughout embryo culture. For handling consistency 
between samples the EOG_TET_NANOG -Dox treatment was also moved into a 
new plate every time the doxycycline was refreshed. At days two and three the 
ESOF plates must be remade with freshly thawed doxycycline. These were gassed 
 
       
        
        
      
40 µL wash drops 
5 µL embryo 
Culture drops 
Mineral oil 
 60 mm petri dish 
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for two hours prior to transfer in a modular-incubation chamber. The embryos 
were then moved into the new ESOF dish, which was returned to the modular-
incubation chamber. This was gassed and placed into the incubator until the 
doxycycline needed to be refreshed again, or until step 2.2.6.6.3.  
2.2.6.6.3 Change of embryo culture media (Day 5) 
The media the embryo is cultured in is designed to best suit the embryos needs for 
healthy growth, by mimicking the environment in vivo. At day five of embryo 
culture, Late Synthetic Oviduct Fluid (LSOF) is required for optimal embryo 
growth. LSOF plates were made and gassed in the modular-incubation chamber 
for two hours prior to use. These plates contained fresh doxycycline for the 
EOG_TET_NANOG +Dox treatment. Whilst moving the embryos from the ESOF 
into the LSOF, they move through three 40 µL wash drops before being placed 
into single culture 5 µL drops. The LSOF plates containing the embryos were then 
placed back into the modular-incubation chamber for a further two days of culture.  
2.2.6.6.4 Day 7 grading and doxycycline refreshing 
A standardised part of embryo culture in the reproductive technologies lab is to 
grade all embryos at day seven to provide an understanding of IVP skills or NT 
development for personal records and as a further step of analysing the 
developmental success of the NT run. The embryo grading was always conducted 
by the same person for consistency using the standard grading regulations 
(Appendix 4). The embryos stage of development was recorded along with a 
number from one to three which represented the morphological quality of the 
embryo. Also at this stage the mCherry and GFP signal was visualised and 
recorded with the Olympus microscope. As the embryos required one further day 
of culture, this also meant that the doxycycline needed to be replenished. Another 
set of LSOF plates were made and gassed for two hours in a micro-incubation 
chamber containing fresh doxycycline in the EOG_TET_NANOG +Dox 
treatment as previously described in section 2.2.6.6.3. EOG_TET_NANOG -Dox 
plates were also made and both treatments were moved into the new plates to keep 
the handling of the embryos consistent. 
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2.2.6.6.5 Day 8 grading and embryo collection 
On day eight, the embryos were at the stage of interest for the research objectives 
in this thesis. They were again graded following the same guidelines as in 
Appendix 4 and were analysed for mCherry and GFP signal. The embryos then 
underwent RNA extraction and cDNA synthesis for qPCR analysis (2.2.6.6.5) or 
were fixed with 4% PFA for ICC (2.2.14).  
2.2.7 RNAGEMTM Tissue PLUS for cells and embryos 
2.2.7.1 Solution preparation 
An RNAGEM Tissue PLUS kit was used to extract RNA from the cells of 
embryos or cell culture tissue and preserved in preparation for cDNA synthesis. 
The RNAGEM mix was prepared before the sample was ready for collection. A 
cell line with a cell count between 50,000 and 500,000 cells requires 1 µL of 
RNAGEM, 5 µL 10x Buffer Silver in 44 µL of DEPC water. A blastocyst sample 
requires 0.5 µl, 1 µL Buffer Silver in 8.5 µL DEPC water.  
2.2.7.2 Sample collection 
The cells must then be prepared for RNAGEM in the tissue culture lab. Cells in 
culture had their media removed. They were washed once in PBS. TrypLE was 
then added to at a quantity which covered the base of the dish. The plate was 
tapped in order to ensure the cells had detached. The trypLE solution containing 
the cells was pipetted into a microcentrifuge tube and spun for 3 minutes at 
1000 rpm. The supernatant is then removed and is replaced with the RNAGEM 
solution prepared earlier. These tubes were then placed on ice and were moved 
into the RNA molecular biology lab. For preparation of an embryo sample, 
microcentrifuge tubes containing the prepared RNAGEM solution were placed on 
ice in order to receive the sample in the embryo lab. Once the tissue was added 
the tubes were spun down using embryology mini centrifuge to ensure the sample 
was immersed in the solution. The microcentrifuge tubes were then placed back 
on ice and were transported to the molecular lab for further processing.  
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2.2.7.3 RNA extraction and DNAse treatment 
The tubes were placed on a heat block for 5-10 minutes depending on cell 
quantity, at 75° C, at which RNAGEM is active. They then were placed back on 
ice where 0.4-2 µL of DNAse treatment was added to each sample, based on 
number of cells.1-5 µL of DNAse buffer was also added to each tube. Tubes were 
placed on a vortex and then briefly spun down. The next step was a five minute 
37° C incubation to activate the DNAse followed by a five minute 75° C 
incubation to inactivate it. Samples were then placed back on ice and spun down 
before 1/10 of the volume of the sample of 10 x TE buffer was added. The 
samples could then be stored at -20° C or could be immediately processed for 
cDNA synthesis (2.2.7.4). 
2.2.7.4 cDNA synthesis 
To begin this process, all samples must be at a quantity of 9 µL. For samples 
containing a greater volume, 9 µL was removed and placed into a new tube for 
further processing and the remaining samples were stored at -80° C. To the tubes 
containing 9 µL of the sample prepared in 2.2.7.3, 1 µL of dNTP mix and 1 µL of 
Random Hexamer Primers were added. The tubes were then incubated at 65 °C 
for five minutes which denatures the secondary binding structure of the mRNA 
and then were plunged into ice for at least one minute which binds the primer. 
These were then spun down to receive the cDNA synthesis mix. This was 4 µL 
5x RT buffer, 4 µL MgCl, 1 µL RNAse Out and 1 µL of SuperScript III.  An 
RT-Negative sample was also prepared for each cDNA batch to analyse potential 
genomic contamination. The SuperScript III was replaced with water for this 
sample. The samples were then run on a cDNA programme in a PCR machine. 
This incubates the samples at 25° C for ten minutes, then, 50° C for 50 minutes 
and finally at 85° C for five minutes. These samples were then stored at -20° C 
and can be analyse using quantitative polymerase chain reaction (qPCR) or 
endpoint PCR.  
2.2.8 DNA extraction 
DNA extraction is a simple method of collecting genomic DNA for analysis. To 
an embryo sample or a cell pellet, 100 µL of lysis buffer and 2 µL of proteinase K 
were added. The samples were then incubated at 55° C for 15 minutes to digest 
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the sample, and then at 95° C for 15 minutes to heat inactivate the proteinase K. 
The samples can then be run on an end point PCR. 
2.2.9 Primer design 
Primers bind to the sequence of interest and amplify them to a testable level. A list 
of primers can be found in the materials section (2.1.11). For the purposes of this 
research, primers specific for the pTRE3G-mCherry vector sequence and 
endogenous NANOG sequence were generated to identify the difference in 
mRNA expression. Homologs were identified through the nucleotide section of 
the National Centre for Biotechnology Informatics (NCBI) website. The basic 
local alignment search tool (BLAST) function was used to identify Bos taurus 
homologs. Once one was selected, the “pick primers” tool was then used. The 
default settings were used except the primer preference was set to a minimum 
PCR amplicon size of 70 bp and a maximum of 300 bp, respectively. In addition 
the primer must span exon-exon junctions. Once the primers were generated, they 
were selected based on their specificity. The primer sequences were then sent for 
primer synthesis.  
2.2.10 Primer re-suspension 
The lyophilised primers were briefly spun down to ensure the pellet was at the 
bottom of the tube. The pellet was then re-suspended in DEPC water at a final 
concentration of 1 mM. A working stock of the combined forward and reverse 
primers was prepared at a final concentration of 10 µM. These were then stored at 
-20 ° C to be used for qPCR (2.2.11) or endpoint PCR (2.2.12). 
2.2.11 Quantitative PCR (qPCR) 
The qPCR method is used to amplify cDNA whilst measuring its amplification in 
order to calculate its original quantity. This allows the comparison of a genes 
expression across cDNA samples generated in section 2.2.7. For the work 
conducted in this thesis a variety of primers were used, the details of which can be 
seen in the methods section (2.1.11). For each qPCR reaction the reaction master 
mix was assembled via the quantities depicted in Table 14. 
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Table 14: Reaction mix components and quantities using Takara for the 
LightCycler2.0. 
Reagents X1 
DEPC water 2.2 µL 
Takara 5 µL 
Primer F & R .8 µL 
 
LightCycler capillaries were arranged in order to receive the appropriate sample. 
The master mix was then pipetted into each capillary tube and the cDNA sample 
was then added. Samples were run in duplicate or triplicate when sample 
availability permitted. Capillaries were then centrifuged for 15 seconds using the 
LightCycler Carousel centrifuge ensuring the samples location at the end of the 
capillary. Samples were then loaded into the LightCycler and the programmed 
temperature regime shown in Table 15 was followed.  
Table 15: LightCycler temperature regime. 
Step Temperature Time 
Denaturation 95° C 10 minutes 
Cycling (x45) 95° C 20 seconds 
 60° C 20 seconds 
 72° C 20 seconds 
Melting curve 95° C then decreasing to 
65° C  
20 seconds 
 Heating to 95° C at 0.2° 
C s-
1
 
NA 
Cooling 4° C NA 
 
The sample produces a number that can be compared to other samples. This is the 
crossover point (CP) in which the amplification of the primer product moves into 
a exponential style amplification increase. The identity of the resulting product 
was confirmed via analysis of the melting curve produced by the LightCycler 
software (2.2.11.1.1). The quantity expression was calculated using the CP and a 
standard curve (2.2.11.1.2) specific to the primer and was expressed as a ratio 
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over the house keeping gene 18S. This works on the assumption that our 
experimental treatments do not impact the expression of 18S. 
2.2.11.1.1 Melting curve analysis 
The melting peak of the product produced during the LightCycler’s program was 
analysed at the end of each run. Each product produced has a specific melting 
temperature in which the strands separate based on base length and GC content. In 
the initial testing of the primer this temperature was revealed and all following 
experiments were compared to check the product was genuine. An inaccurate 
melting peak could be the result of genomic or cDNA contamination of the 
sample, or primer dimer, where the primer binds to itself and creates a subsequent 
sequence. For each primer run conducted a no-template control (NTC) was run in 
parallel. This sample either produced a flat line with no melting peak, or showed a 
standard primer dimer peak, consistent with that primer. A positive template 
control (PTC) was also run in parallel. This sample contained a gel elute of the 
band produced in section 2.2.11.1.5. The band length was checked against the 
expected length provided by the information pamphlet that came with the primer. 
The band was eluted using the E.Z.N.A gel elution kit (section 2.2.11.1.5), 
resulting in a concentrated solution of the primer product. These were often 
diluted 1/100 to achieve a reasonable CP. When this was run through the 
LightCycler it produced a melting peak to compare the cDNA samples to and also 
validated the experiment, showing that it worked.  
 
All qPCR experiments throughout this research underwent melting curve analysis. 
Each CP produced by a sample was only analysed if the melting peak of that 
sample matched what was expected from that primer pair (Table 11). The result 
was discarded if it was not a match. A NTC was also run alongside all 
experiments. This was expected to flat line. If it produced a specific peak, the 
entire run of samples was discounted as the CPs could have been altered by the 
presence of something in the master mix. 
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2.2.11.1.2  Standard curve generation  
A standard curve is used to provide a calculation in which the concentration can 
be determined for each CP. Primers were ordered as described in section 2.2.9. 
Once they arrived, they underwent analysis via qPCR to see if the CP and melting 
peak produced was consistent. They were then validated by running the result of 
the qPCR on a gel to check the band size they produced. Once the band was 
confirmed to be the correct size, it was extracted using the E.Z.N.A protocol 
(2.2.11.1.5). This gel elute is a highly concentrated solution of the primer product 
which was used to generate the standard curve. This was serially diluted to 5-log 
dilutions. A master mix for the primer was made following the reaction mix 
guidelines explained in Table 14. Each dilution set was run in duplicate, triplicate 
or quadruplicate depending on how dilute the sample was, as higher dilutions 
required more replicates to obtain a more accurate result. The standard program 
from the LightCycler was run (Table 15) and the curves were generated using the 
LightCycler software. The data generated by the LightCycler was exported to 
Excel. The data was graphed and a trend line equation and R value was generated 
for each graph. A graph with an efficiency within a 0.5% range of 2, was used to 
statistically analyse each CP in accordance with the gene analysed.  
2.2.11.1.3 Statistical analysis of CPs using the standard curve 
The relative units (RU) were generated via the use of the standard curve of each 
primer for each sample.  The CP generated by the qPCR experiment on the 
samples was incorporated into an equation (Equation 2), along with the primers 
standard curve values.  
Equation 2: 𝐑𝐞𝐥𝐚𝐭𝐢𝐯𝐞 𝐮𝐧𝐢𝐭𝐬 𝐜𝐚𝐥𝐜𝐮𝐥𝐚𝐭𝐢𝐨𝐧 
𝑹𝑼 = 𝑬𝑿𝑷 (−(𝑪𝑷 𝒗𝒂𝒍𝒖𝒆 − 𝒙 𝒗𝒂𝒍𝒖𝒆/𝒚 𝒗𝒂𝒍𝒖𝒆) 
All samples were also analysed with a house keeper gene, either GAPDH or 18S. 
The RU for the samples of the target gene was then expressed as a ratio over an 
RU from the house keeper gene. This samples number could then be compared to 
numbers generated for other samples and revealed which sample was expressing 
more or less of the gene of interest. These results were graphed and the data 
underwent a Students t-test or Fishers exact test to determine if the difference 
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between treatments was statistically significant (P < 0.05). Students t-tests were 
conducted on logged values. Samples were graphically presented in column 
graphs in either log or fold change format. Fold change graphs were generated by 
calculating the ratio of expression of the EOG_TET_NANOG +Dox treatment 
over the control; all genes were then presented on one fold change graph. Error 
bars were calculated based on the standard error of the mean (SEM) of all 
biological replicates. Log graphs were generated by unclogging logged values 
(generated for statistical analysis) and setting the graph to a log setting. SEM was 
calculated using Equation 3 and Equation 4. 
Equation 3: Equation to calculate positive error in logarithmic graph. 
𝐸𝑟𝑟𝑜𝑟 𝑢𝑝 = 
𝑃𝑜𝑤𝑒𝑟(10, 𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑙𝑜𝑔10 + 𝑠𝑡𝑑𝑒𝑣 𝑙𝑜𝑔10 − 𝑃𝑜𝑤𝑒𝑟(10 𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑙𝑜𝑔10 𝑣𝑎𝑙𝑢𝑒) 
Equation 4: Equation to calculate negative error in logarithmic graph. 
𝐸𝑟𝑟𝑜𝑟 𝑑𝑜𝑤𝑛 = 
𝑃𝑜𝑤𝑒𝑟 (10, 𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑙𝑜𝑔10) − 𝑃𝑜𝑤𝑒𝑟(10, 𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑙𝑜𝑔10 − 𝑠𝑡𝑑𝑒𝑣 𝑙𝑜𝑔10) 
 
2.2.11.1.4 Calculation of absolute copy number of mRNA 
transcripts from concentration 
The molecular weight (bp) for the transcript of interest was converted into M 
[g/mol]. Then the ng/µL value of the primer gel elute derived in section 2.2.11.1.2 
was entered into a table where the log-5 dilution series used to create the standard 
curve was recalculated into the ng/µL unit. This value was then multiplied by 
1000 to derive the value of ng/mL. This value was then added to Equation 5 to 
calculate mol per mL. 
Equation 5: Mol per mL calculation. 
𝑛 = 𝑚/𝑀 
 
This value was again multiplied by 1000 to calculate the mols per litre. The 
number of molecules per litre was then calculated using Avogadro’s constant 
6.002214129 x 10 
23
. This was converted back into mL by multiplication of 0.001. 
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The concentration was calculated based on 2 µL of template in the 10 µL qPCR 
reaction mix. This was calculated using Equation 6 which resulted in mol/L. 
Equation 6: Concentration calculation. 
𝐶 = 𝑛/𝑉 
The number of molecules in the litre was calculated by again using Avogadro’s 
constant. Finally the number of molecules per 10 µL reaction was able to be 
calculated by multiplying the mol/L in the 10 µL reaction mix by 1.00 E -05 to 
convert to the 10 µL volume, then multiplying that number by Avogadro’s 
constant. For embryo samples the copy number was normalised over the number 
of embryos within each sample. Cell samples consistently contained 500,000 cells 
per sample so did not require normalisation.  
2.2.11.1.5 Gel elution for positive template controls and 
standard curves 
To generate enough PCR product to produce a standard curve, a DNA band of the 
product was extracted and eluted to produce a highly concentrated solution of the 
primer’s product. End point PCR described in section 2.2.12 was used to amplify 
the primer product from a sample containing the target gene. The resulting 
solution was subject to agarose gel electrophoresis (2.2.13) to confirm that the 
band that was in the correct size range and was then carefully cut out of the gel 
using a scalpel blade. The gel section containing the DNA fragment was then 
placed into a pre-weighed 1.5 mL microcentrifuge tube. The tube containing the 
gel section was then re-weighed to calculate the weight of the gel section. The 
E.Z.N.A kit protocol was then followed. Binding buffer was added to the tube at 
1 mL per 1 g of band. This was then added to a heated shaker at 60° C, until the 
gel had completely dissolved into the solution. The solution was then pipetted into 
a HiBind DNA spin-column which held the DNA as the dissolved gel moves 
through during a two minute spin at 14,000 rpm at RT. The DNA in the column 
was then washed with a wash buffer and eluted into a new tube with an elution 
buffer. The concentration and purity of the solution was then measured using a 
NanoDrop Spectrophotometer. A 1 µL drop was pipetted onto the NanoDrop 
pedestal after it had been blanked with DEPC water. The DNA was measured at 
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Absorbance (A) of 260 nm and the concentration was reported in ng/µL. A pure 
DNA sample is expected to produce an A260/280 ratio above 1.8. The solution can 
then be used to generate standard curves (2.2.11.1.2) or as a positive template 
control for qPCR analysis (2.2.11) 
2.2.12 Endpoint PCR 
End point PCR is a more primitive version of qPCR. It works on the same 
principles but an endpoint PCR machine does not have the capability of 
measuring the quantity of the gene as it is amplified. Instead it can only detect if a 
gene is present or absent in a tissue. This can only be visualised when the end 
product is run on through gel electrophoresis.  
 
For each cDNA or DNA sample a 25 µL PCR reaction was prepared in a PCR 
tube. The reaction mix is outlined in Table 16. To each PCR tube, 1 µL of sample 
was added or 1 µL of water for a negative control.  
Table 16: Endpoint PCR reaction mix. 
Reagent 1x 
10x buffer mix 2.5 µL 
dNTPs 0.5 µL 
F and R primers 1 µL 
Taq DNA Polymerase 0.2 µL 
H2O 20.8 µL 
Total 25 µL 
 
 
The samples were then run on a PCR machine which has a number of different set 
programmes depending on how many cycles needed to be run and which primers 
were being used. The parameters are displayed in Table 17. 
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Table 17: Outline of standard endpoint PCR reaction parameters. 
Step Temperature (°C) Time  Cycles  
Initial 
denaturation 
95 5 minutes 1 
Denaturation 94 30 seconds  
Annealing 50-60 (depending on 
the primer) 
30 seconds 30-45 depending on 
primer 
Extension 72 30 seconds  
Final extension 72 7 minutes 1 
Cooling 4 On hold  NA 
 
Once the PCR reaction was complete, the samples were analysed using gel 
electrophoresis (section 2.2.13) to determine whether or not a band is present. 
2.2.13 Gel electrophoresis 
Gel electrophoresis was used to visualise the product of end point PCR or qPCR 
and to identify the base pair length. First, the agarose gel mould was prepared. 
The size of the mould depended on the number of samples. The required 1 X TAE 
buffer to fill the gel mould was measured in a volumetric flask and the quantity of 
agarose powder was weighed. The gel can be made at a concentration anywhere 
between 1-2.5% agarose depending on the parameters of the experiment. The 
powder was then added to the TAE buffer and the solution was microwaved in 
order to dissolve the agarose crystals. Once the agarose was melted and the 
solution had cooled to a heat where it could be touched, 1 µL of SYBR safe was 
added per 10 mL of agarose solution. The solution was then poured into the 
mould and left to set at RT.  
 
Once the gel had solidified, it was placed into a gel electrophoresis tank. A 1 kb 
ladder was added to each end well to act as a marker by which the samples bands 
could have their band length measured. A 10 µL sample of the PCR or endpoint 
PCR product was transferred onto a piece of Parafilm and was mixed with 2 µL of 
loading dye. Each sample was then loaded into its designated well. The lid was 
placed back on the tank and the voltage was set from 80-120 volts depending on 
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the thickness of the gel. Once the loading dye had travelled 3/4 of the way through 
the gel, electrophoresis was stopped. The bands were then visualised under UV 
light and photographed using the gel doc and Quantity one software. 
2.2.14 Immunocytochemistry (ICC) 
Immunocytochemistry (ICC) offers visualisation of the cellular localisation of 
gene expression via a fluorescent signal attachment to the target protein. Two 
methodologies were developed for ICC on cell lines and embryos. For cell lines, 
cells were grown on 10 mm circular coverslips which were previously placed on 
the bottom of a tissue culture dish prior to the cells culture. This allowed the cells 
to adhere and grow on the surface of the coverslip. The solutions are then placed 
on to the coverslip, in a dish with the cell side up or the coverslips can be placed 
cell side down onto a drop of solution. When this protocol is conducted on 
embryos, an embryo was placed into a 96 well conical plate where each solution 
is in a different well and the embryos are moved from well to well as required. 
The two day ICC protocol was carried out at RT unless otherwise stated. Wash 
steps were at a duration of five minutes and require PBS for cells and PBS-PVA 
for embryos to prevent the embryos from attaching to the plate.  
 
Firstly, the sample must be washed three times from the media in which it has 
been growing to remove protein growth nutrients. This was achieved via three 
washes. The samples were then fixed in freshly depolymerized 4% PFA for 15 or 
30 minutes at 4° C for cells and embryos respectively. The samples were washed 
three times. To reduce background staining, the samples were then incubated in 
NH4Cl for 10 minutes which quenches the aldehyde groups. This was followed by 
one wash. Then, to increase the permeability of the cells, the samples were 
incubated in 0.1% Triton-X for 10 or 15 minutes for cells or embryo, followed by 
one wash. To avoid false positive staining the samples were blocked in 5% serum 
of the species in which the secondary antibody was raised for 30 minutes for a cell 
sample and 90 minutes for an embryo sample. This was commonly either donkey 
or goat serum. 
 
The samples were then transferred to a humidified chamber and incubated with 
50 µL of primary antibody overnight at 4° C. This binds to the protein of the gene 
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under investigation. The antibodies were diluted in blocking solution. A list of 
antibodies and dilutions used can be found in the materials section 2.1.9. A 
control treatment was included where no primary antibody was applied. This 
control determined the intensity of background fluorescence produced by the 
secondary antibody. This incubation must be conducted in a humidified chamber. 
For cells this means the antibody was pipetted in 50 µL drops onto Parafilm in a 
petri dish lined with damp filter paper. The petri dish is then wrapped with 
Parafilm. For embryos, the surrounding wells in the 96 well plate were filled with 
dH2O, the plate was then wrapped in Parafilm. The primary antibody incubation 
was left overnight at 4° C. 
 
On the second day, the samples were washed three times to remove unbound 
antibody before they are placed in the secondary antibody. The secondary 
antibody was also diluted in the blocking solution. The DNA stain Hoechst was 
also added to the secondary stain incubation. The secondary antibody was in a 
humidified chamber at 37° C for 30 minutes. The samples were then washed three 
times, followed by a brief wash in dH2O.  
 
The samples were then mounted. For cells, the coverslip was placed cell side 
down onto 3 µL of mounting media on a frosted slide. For embryos, 3 µL of 
mounting media was pipetted onto the frosted slide and the embryos were then 
mouth pipetted into the mounting media followed by the placement of a circular 
cover slip on top. The slides were stored in at 4° C until photographs were taken 
using a digital camera and microscope. 
2.2.14.1 Photography of ICC samples 
The fluorescent signal was visualised on the Olympus microscope. The images 
were taken using Spotbasic software. When possible, images were taken in black 
and white of three different wave length channels; 488, 568 and 405. The 
exposure time for all channels was established upon the first observation of the 
samples and this was kept consistent throughout the analysis of that run. This 
allowed the images to be comparable, and accurately demonstrates the 
background fluorescence from the secondary antibody shown in the control 
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treatment. The images were then re-coloured using the computer software 
programme ImageJ. From the look up tables menu a colour was selected based on 
the actual colour photographed. On occasion colour images were taken using the 
colour setting on the camera. A scale bar was added with the Spotbasic software. 
In addition, the three images taken were composed into a merge image to overlay 
the location of protein expression.  
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 Results Chapter 3:
 Primers which distinguish between ectopically and 3.1
endogenously expressed NANOG 
A series of primers were designed using the NCBI BLAST function. These 
primers were to determine the difference between the ectopically and 
endogenously expressed NANOG.  
 
 
Figure 15: Vector maps of DNA constructs used in this study. A. Vector sequence 
containing bovine NANOG gene (green), with the endogenous NANOG primer and 
ectopic NANOG primer binding locations depicted with green arrows. B. pTRE3G-
mCherry vector sequence containing codon-optimised bovine NANOG with the binding 
locations for the ectopic NANOG primers. C. Alignment of mRNA sequences for bovine 
NANOG (from vector sequence) and codon-optimised NANOG. The consensus sequence 
is 905 nt in length with the green bar indicating sequence sections that match with 100% 
identity, white indicates discrepancies between the two sequences. An enlargement of 
mRNA 1-50 illustrates 14 differences at the nucleotide level. D. Alignment of amino acid 
sequences for vector A bovine NANOG and vector B codon-optimised NANOG protein.  
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Image A. of Figure 15 shows the reverse primer for the endogenous NANOG 
sequence binding in the open reading frame of the bovine NANOG sequence. The 
forward primer binds in the bovine genomic sequence immediately prior to 
NANOG and does not bind to the pTRE3G-mCherry vector. Therefore, this primer 
will only bind the mRNA of NANOG expressed by the embryo. Image A. of 
Figure 15 also shows the forward primer for the ectopic NANOG binding the 
vector before the NANOG sequence. The reverse primer does not bind to the 
bovine NANOG sequence, but does bind to the codon-optimised NANOG 
sequence (Image B, Figure 15) Therefore, this primer will only bind the mRNA 
produced by the vector. Image C. of Figure 15 shows the differences in mRNA 
sequences for the bovine NANOG and codon-optimised NANOG sequences, 
where the amino acid sequences align 100%, forming the same protein structure 
(Image D, Figure 15). 
 NT with unsorted donor cells overexpress NANOG but do 3.2
not affect targets 
There were three NT runs conducted on the EOG_TET_NANOG cell line before 
it was sorted for high mCherry expression using FACS. The aim of these initial 
NT runs was to analyse how well the pTRE3G-mCherry vector was transcribed 
and translated within the embryo, to optimise the cell culture and embryo culture 
for most effective results, and to analyse how efficiently the cell line was 
reprogrammed.  
. 
A total of 60 bovine ovaries were aspirated for each run, generating approximately 
200 oocytes. Of these, 140 were enucleated. The cell line was not induced prior to 
NT and was synchronised to cell cycle G0 via a six day serum starvation. For each 
treatment, 30 embryos were derived. In an earlier analysis it was concluded that 
the day of doxycycline treatment was to be from day 0. At day 7, the embryos 
were graded based on morphology and the mCherry signal was visualised and 
graded based on strength (data not shown). The samples were then sorted and 
blastocysts grade 1-2 underwent RNA extraction and cDNA synthesis. These 
samples were then analysed via qPCR for ectopic NANOG, endogenous NANOG 
and XIST to understand the transcriptional effects resulting from the vector.  
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Figure 16: Fold change of ectopic NANOG, endogenous NANOG and XIST 
expression relative to 18S EOG_TET_NANOG +Dox over control. cDNA was 
extracted from blastocysts grade 1-2 which were pooled in groups of 5-10. n= number of 
biological replicates, N= number of blastocysts. EOG_TET_NANOG +Dox n= 3 N= 19. 
EOG_TET_NANOG -Dox n= 3 N= 21.Target genes were normalised over 18S 
expression in RU. Results were logged and averaged. Error bars indicate ± SEM. 
Students t-tests were conducted to conclude significance (P<0.05). * denotes significance 
(P<0.05).  
The ectopic NANOG was significantly overexpressed in embryos exposed to 
doxycycline in comparison to non-induced embryos 20-fold (P = 0.008). The 
endogenous NANOG and XIST expression show no significant differences 
between treatments P = 0.443 and P = 0.335, respectively. Since there was no 
effect on NANOGs targets, it was decided that the EOG_TET_NANOG cell line 
should be sorted against mCherry expression in order to achieve a higher 
population of NANOG expressing cells.   
 Characterisation of FACS sorted donor cell line 3.3
EOG_TET_NANOG  
The developmental history of the FACS sorted doxycycline-inducible 
EOG_TET_NANOG cell line was explained in section 2.2.3. This cell line was 
derived in order for it to be used for the production of embryos which overexpress 
NANOG via NT. Prior to its use in NT it must be again validated (after sorting) 
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for its mCherry and NANOG expression via qPCR and ICC. When analysing the 
cell lines inducibility, a non-induced EOG_TET_NANOG control was important 
to test alongside. This was to analyse the difference in expression between the 
induced and non-induced treatments. However, a further control was also required 
for many experiments. This was the EOG_TET cell line described in section 2.2.3. 
This cell line is the parental line to EOG_TET_NANOG, it does not contain the 
NANOG gene but does constitutively express Tet activator (TET 3G). Cells were 
observed based on morphology to identify any possible changes as a result of 
culture conditions or induction.  
3.3.1 Cell line gene expression analysis of overexpressed NANOG 
has no effect on targets 
Cells were processed via the RNAGEM protocol to extract RNA, converted to 
cDNA and analysed via qPCR with ectopic and endogenous NANOG primers, 
along with XIST, OCT4 and SOX2 (Figure 17). Section A. of Figure 17 shows that 
the increase in ectopically expressed NANOG is four orders of magnitude higher 
in the non-induced treatment than in the non-induced EOG_TET control. The 
induced treatment is significantly higher than the non-induced EOG_TET and 
EOG_TET_NANOG treatments by ten and four orders of magnitude. No other 
genes were significantly affected by the over expression of NANOG (Figure 17, 
Section B. C. D. E.) The absolute copy number of the ectopic NANOG transcript 
was calculated, the results of this can be seen in Figure 18. The copy number of 
the induced EOG_TET_NANOG is significantly higher than the 
EOG_TET_NANOG and EOG_TET non-induced controls by five and ten orders 
of magnitude. Non-induced EOG_TET_NANOG is five orders of magnitude 
higher than the non-induced EOG_TET control.  
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Figure 17: qPCR analysis of the EOG_TET_NANOG cell line, EOG_TET_NANOG 
+Dox compared to EOG_TETNANOG –Dox and EOG_TET -Dox controls. Target 
gene values were normalised against 18S expression in RU. Results were logged and 
averaged. n= biological replicates. Error bars represent ± SEM. Students t-tests were 
conducted to test significance (P<0.05) A. Ectopic NANOG expression. B. Endogenous 
NANOG expression. C. XIST expression. D. OCT4 expression. E. SOX2 expression. Bars 
denoted with an A are significant from the EOG_TET_NANOG +Dox treatment. Bars 
denoted with a B are significant from the EOG_TET_NANOG -Dox treatment. Bars 
denoted with are C are significantly different from the EOG_TET treatment. 
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Figure 18: Copy number of ectopic NANOG transcript shows significance between 
all treatments. Copy number was calculated based on protocol outlined in section 
2.2.11.1.4. n= number of biological replicates. Students t-test were conducted to evaluate 
significance (P<0.05). Bars denoted with A are significant from EOG_TET_NANOG 
+Dox (P<0.001), bars denoted with B are significant from EOG_TET_NANOG –Dox 
(P<0.001), bars denoted with C are significant from EOG_TET –Dox.  
3.3.2 EOG_TET_NANOG cell line doxycycline-induced treatment 
positive for NANOG protein 
Fibroblasts were thawed (2.2.4.1) into a tissue culture dish containing glass 
coverslips. They were cultured for 48 hours in which the induced 
EOG_TET_NANOG treatment was induced throughout. This was conducted in 
standard cell culture media. The fibroblasts were then stained for NANOG protein 
using the ICC protocol (section 2.2.14) (Figure 19). For the NANOG staining 
non-induced EOG_TET_NANOG and EOG_TET treatments were used as 
controls. A Donkey anti Mouse Alexa Fluor® 488 secondary antibody was used. 
Images of the mCherry signal were also taken to compare with NANOG protein 
localisation. The number of cells expressing NANOG and mCherry were counted 
in a blind analysis of ten different fields of view of each treatment (Figure 20).  
The treatment names were encoded and the party who conducted the count was 
unaware of the projects details. 
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Figure 19: ICC analysis of NANOG protein in the EOG_TET_NANOG cell line. 
Deno Denote cells which are positive for all signals.     Denote cells which have weak 
mCherry signal and strong NANOG. O Denotes a cell which has a Hoechst signal but is 
negative for both mCherry and NANOG. Images pseudo coloured with ImageJ. Hoechst 
DNA stain (blue), mCherry signal (red), Alexa Fluor® 488 secondary stain for NANOG 
(green). 
  
Figure 20: Significantly higher percentage of antigen positive cells for mCherry and 
NANOG in the EOG_TET_NANOG +Dox treatment than controls. Students t-tests 
were conducted to test significance (P<0.05). ** denotes significance from controls 
P<0.001. n= biological replicates. N= number of cells counted. Error bars represent ± 
SEM.  
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There was no mCherry or NANOG signal in the non-induced EOG_TET or 
EOG_TET_NANOG control. The mCherry count was 55 ± 15% which is much 
lower than what was seen in a flow cytometry reading just after cell sorting for the 
mCherry signal. The NANOG positive cells were higher than that of the mCherry 
signal, at 58 ± 9%. 
 Inactive X-chromosome analysis of seven cell lines 3.4
3.4.1 Sexing analysis confirms EOG_TET-NANOG as female 
compared with five control cell lines 
The cell lines were analysed via PCR using sexing primers in order to confirm 
their sex. DNA samples for a seven cell lines were prepared via the genotyping 
technique as described in section 2.2.8, this consisted of the cell line focused on in 
this research, EOG_TET_NANOG and all its parental cell lines which were 
EOG_TET and EOG. The cell lines LFC2 and EFC1B were female controls of 
follicular cells isolated from adult ovaries and LJ801 was a male control of skin 
fibroblasts isolated form an ear biopsy. Seven PCR reactions were performed 
using DNA extracted from these cell lines with sexing primers (Figure 21) and or 
a multiplex of Y chromosome primers (Figure 22). Positive and negative controls 
were included. Finally, amplified products were run on a 2% agarose gel for 1 
hour at 90 V. 
 
Figure 21: Agarose gel electrophoresis of DNA extraction of seven cell lines confirms 
six female and one male cell line. Run for 1 hour at 90 V, 2% agarose. 
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The sexing set of primers contains one primer pair specific for the X-chromosome 
and one primer pair specific for the Y chromosome. The expected PCR results 
using these primers is the observation of an X-chromosome band at 262 bp, and 
the Y chromosome band at 202 bp on the agarose gel. Cell lines that had both 
bands visible were confirmed to be male, cell lines that only have the X band 
visible were confirmed to be female. EOG_TET_NANOG, EOG_TET, EOG, 
EFC1B and LFC2 cell lines were female and the LJ801 cell line was male (Figure 
21). 
 
Figure 22: Agarose gel electrophoresis of multiplex PCR of seven DNA samples 
confirms six female and one male cell line. Run for 1 hour at 90 V, 2% agarose.  
The Y chromosome specific primers used in this multiplex PCR were DDX3Y, 
USPY9 and ZRSRY. The bands produced by each primer pair were 225, 285 and 
158 bp respectively. Figure 22 shows the PTC for USP9Y and ZRSRY (DDX3Y 
PTC was unavailable). These were the result of a PCR experiment conducted on a 
gel elute of the DNA band produced by each primer pair, this is highly 
concentrated which is why these two bands are much brighter than the bands in 
the samples. The expected result is that female cell lines will produce no bands, 
where male cell lines will have three. LJ801 is the only male cell line. No cell 
lines confirmed female in Figure 22 contain any male contamination. In 
conclusion, EOG_TET_NANOG and all its parental cell lines were female, LJ801 
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was a male cell line and there was no contamination of male cells within 
EOG_TET_NANOG or any of its parental lines.  
3.4.2 Male and female cell lines have significantly different Xist 
expression 
The second objective for this research is an investigation into the expression of 
XIST, and if it is changed by the overexpression of NANOG in the induced 
EOG_TET_NANOG treatment. A series of male and female cell lines were 
analysed via qPCR for XIST and DDX3Y gene expression. This was to analyse if 
the XIST expression of the induced EOG_TET_NANOG treatment was 
significantly lower than other females as a result of the overexpression of 
NANOG. For this series of experiments the house keeping gene 18S was initially 
used (Figure 23 A/B), but showed too much  variation. 
 
Figure 23: qPCR analysis of XIST and DD3XY expression of female and male cell 
lines show greater variability with 18S housekeeper than GAPDH. XIST and DDX3Y 
expression was normalised against either 18S or GAPDH expression in RU. Error bars 
represent + SEM. n= biological replicates. Figures A and B have 18S as a housekeeping 
gene where figures C and D have the GAPDH house keeping gene. Cell lines LJ801 and 
SNAZY are male, cell lines EFC1B, LFC2, EOG, EOG_TET, EOG_TET_NANOG were 
all female. 
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GAPDH was then used as it showed less variation and gave a clearer picture of 
gene expression (Figure 23 C/D). For this series of experiments the same set of 
cell lines were used as in section 3.4.2, however, there was one more male control 
included. This was to be sure that the LJ801 was representative of normal male 
expression. The additional male cell line was SNAZY, a bovine skin fibroblast 
sample created from an ear biopsy. 
 
Figure 24: qPCR analysis of XIST and DD3XY on eight cell lines show significant 
differences between female and male lines. Target gene values were normalised against 
GAPDH expression in RU. Results were logged and averaged. n= biological replicates. 
Error bars show the ± SEM. Students t-tests were conducted to measure significance of 
pooled male and pooled female groups (P<0.05). Image A. A and B are significantly 
different from one another (P<0.001).Image  B. A and B are significantly different (P = 
<0.001). 
The XIST expression of the grouped female cell lines is significantly higher than 
the grouped male cell lines by around two orders of magnitude. The induced 
EOG_TET_NANOG treatment was not significantly different from the other 
female cell lines, nor is the EOG_TET_NANOG treatments when compared as a 
group. The expression of DD3XY was significantly higher by four orders of 
magnitude in the two male cell lines than in the female cell lines. 
3.4.3 H3K27me3 staining does not identify inactive X-
chromosome 
An issue of interest was whether the inactive X-chromosome could be visualised 
in fibroblast cells and further more if the overexpression of NANOG would 
decrease the number of visible inactive X-chromosomes in the induced 
EOG_TET_NANOG treatment. In a literature search, no published data 
describing this phenomenon has been identified in this cell type before. Therefore, 
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an assay was set up with a series of female and male fibroblast controls to test this 
hypothesis. This consisted of EOG_TET_NANOG parental cell lines, EOG_TET, 
and EOG. LFC2 and EFC1B were female controls of follicular cells isolated from 
an adult ovary and LJ801 was a male control of skin fibroblasts isolated from an 
ear biopsy. Cells were thawed into tissue culture dishes containing glass cover 
slips and were cultured for 48 hours until they were between 60 and 90 % 
confluent. The ICC protocol was carried then out. As XIST is a lncRNA there was 
no direct protein to stain for. Instead an H3K27me3 antibody was used as a proxy. 
H3K27me3 is present across all chromosomes but is enriched around the inactive 
X-chromosome, which produces a clear dot or cloud around the inactive X-
chromosome [130]. Cells were co-stained with a Hoechst DNA stain. A Donkey 
anti Rabbit Alexa Fluor 488 secondary was used. The staining protocol did work 
although the intense inactive X-chromosome H3K27me3 cloud was never observed 
with 100 % certainty (Figure 25).  
 
Figure 25: Seven cell lines stained for the inactive X-chromosome H3K27me3. 
Images pseudo coloured with ImageJ. Hoechst DNA stain (blue), H3K27me3 stain with 
Alexa Fluor® 488 Fluor secondary (green). 
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A blind count was set up to determine if any of the potential H3K27me3 cloud dots 
were valid. Three random fields of view from each treatment were counted and 
each potential dot was identified with a red arrow. The count was conducted with 
encoded cell names by a party who was unaware of the details of this project. An 
example of the potential H3K27me3 clouds can be seen in Figure 26 and the results 
of this count can be seen in Figure 27.  
 
Figure 26: ICC staining of H3K27me3 of seven cell lines where potential H3K27me3 
clouds are indicated with red arrows. EOG_TET_NANOG –Dox image did not contain 
arrows. Images are presented in black and white for better definition of potential 
H3K27me3 clouds. 
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Figure 27: Bar graph depicting the percentage of cells containing a potential inactive 
X-chromosomes represented by H3K27me3 clouds. n= biological replicates, N= 
number of cells counted. Student t-test were conducted for significance (P<0.05). Error 
bars represent + SEM. 
The statistical analysis of the count revealed that there was no significant 
difference in the number of potential H3K27me3 clouds between the female cell 
lines and the male cell line control.  
 Characterisation of cell line after serum starvation 3.5
Prior to NT, the cell line must undergo serum starvation to synchronise all cells 
into the G0 phase of the cell cycle, as this phase is optimal for NT. The initial 
characterisation of the EOG_TET_NANOG cell line was conducted under 
standard culture conditions as described in section 2.2.2. It was important to 
analyse if the expression of the pTRE3G-mCherry vector was altered by the low 
serum culture conditions for G0 synchronisation. Cells were also observed on a 
morphological basis to identify any possible changes that may have occurred due 
to serum starvation.  
3.5.1 Serum starvation causes a significant decrease in ectopic 
NANOG expression 
The EOG_TET_NANOG cell line was analysed for the expression of the 
pTRE3G-mCherry vector sequence with the ectopic NANOG primer after 6 days 
of serum starvation (Figure 28). These cells were processed via RNAGEM and 
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cDNA libraries were derived from induced non-starved and serum starved 
induced and non-induced treatments. 
 
Figure 28: Ectopic NANOG expression is significantly decreased by serum 
starvation. ss denotes serum starved treatments. Ectopic NANOG values were normalised 
against 18S in RU. Results were logged and averaged. n = biological replicates. Error 
bars represent ± SEM. Students t-tests were conducted to measure significance (P<0.05). 
A denotes significant difference from EOG_TET_NANOG +Dox, B denotes significant 
difference from EOG_TET_NANOG +Dox ss, C denotes significant difference from 
EOG_TET_NANOG -Dox ss. 
Both the serum starved cell treatments had significantly less expression of ectopic 
NANOG than the induced non-starved treatment by two and seven orders of 
magnitude, respectively (EOG_TET_NANOG +Dox ss P = 0.02, 
EOG_TET_NANOG –Dox ss P = <0.001). Within the serum starved treatments 
the induced and non-induced treatment remains significantly different from each 
other (P = 0.02). 
3.5.2 NANOG positive cells are present after serum starvation 
The serum starved cells were stained for NANOG to see how the impact of serum 
starvation affected the ectopic NANOG on a protein level (Figure 29). The 
EOG_TET_NANOG cell line was thawed (section 2.2.4) into two tissue culture 
dishes containing glass cover slips. The cells were cultured in low serum media 
for 6 days of which the induced serum starved treatment was induced throughout. 
A serum starved non-induced treatment was a control. On day 4 a new vial of 
EOG_TET_NANOG cells was thawed and non-starved induced and non-induced 
treatments were made in standard cell culture media, of which the induced 
treatment was induced for 48 hours. Coverslips from all four treatments were 
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stained for the protein NANOG using the ICC protocol (section 2.2.14). A 
Donkey anti Rabbit Alexa Fluor® 488 (Green) secondary was used. Cells were 
co-stained for DNA with Hoechst. Images of the mCherry signal were also taken. 
 
Figure 29: NANOG and mCherry protein show lower intensity of signal after serum 
starvation. ss denotes serum starved treatments. Blue and red images were pseudo 
coloured using ImageJ software. Green images were photographed in colour. Hoechst 
DNA stain (blue), mCherry signal (red) and NANOG indicated with Alexa Fluor 488 
(green).  
The NANOG protein is present in the induced serum starved treatment. However, 
the signal is weaker than what is seen in the induced non-starved treatment. A 
count of mCherry and NANOG antigen positive cells was conducted (Figure 30). 
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Figure 30: mCherry positive cells are not affected and NANOG positive cells 
increase by serum starvation over total cells. ss denotes serum starved treatments. 
Error bars represent ± SEM. Students t-tests were conducted to test significance (P<0.05). 
** denotes P<0.001 from EOG_TET_NANOG +Dox equivalent treatment. A is 
significantly different from std +Dox (0.008).  
There was around a 41 ± 17% survival rate in total cell number of the serum 
starved cells. When expressed as a percentage there was no significant difference 
between mCherry expression in the standard cell culture versus serum starved 
cells (P = 0.862). Also when expressed as a percentage the population of cells that 
are NANOG positive is significantly higher (0.008) in the serum starved cells than 
in the cells under standard culture. 
3.5.3 Hygromycin resistance is doxycycline-inducible 
In an attempt to enrich for mCherry positive cells, serum starved cells were 
cultured in hygromycin as this was the selection marker for the Tet system and 
should select for cells that contain it. Hygromycin was added to the serum starved 
cells at maintenance levels for the standard 6 day duration of serum starvation. A 
control was also prepared without hygromycin. Live images of this serum 
starvation culture were taken with the EVOS and can be seen in Figure 31. 
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Figure 31: EOG_TET_NANOG –Dox ss has 100% mortality when cultured in 
hygromycin. ss denotes serum starved treatments. Live images of EOG_TET_NANOG 
+Dox ss and EOG_TET_NANOG –Dox ss cells treated with hygromycin with a no 
hygromycin control. Images taken on EVOS microscope.  
Cells in the induced, serum starved, hygromycin treatment appear to have a more 
intense mCherry signal overall than those in the induced, serum starved, no 
hygromycin control. The non-induced hygromycin treatment had complete cell 
death where the non-induced no hygromycin treatment had a small percentage of 
death due to low serum conditions. 
 Characterisation of EOG_TET_NANOG NT embryos 3.6
There were 7 NT runs conducted on the EOG_TET_NANOG cell line after it was 
sorted against mCherry. The parameters for oocyte recovery and reconstruct 
numbers were the same as the NT runs conducted prior to FACS (Section 3.2). 
The development of embryos was recorded on day 7 and day 8 of each NT run 
using the grading protocol outlined in Appendix 4. The results of the blastocyst 
development can be seen in (Table 18 and Figure 33). 
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Table 18: Overexpression of NANOG has no effect on embryo development for day 
8 embryos. 
a 
Embryos were cultured in medium containing doxycycline versus no 
doxycycline throughout embryo culture. N
b
 number of independent runs. 
C
 Proportion 
placed into IVC (N) that developed into day 8 blastocysts grades 1-3 (B
1-3
) 
D
 Proportion 
of all B 
1-3
 that are B 
1-2
. Students t-tests were conducted (P<0.05). 
Treatment 
a
 n
b
 N % Fused  
(% ± SD) 
% B
1-3 
(% ± SD)
c
 
% 
B1-2  
(% ±SD)
d 
Percentage  
(±SD) B
1-2
/B
1-
3
) 
EOG_TET_NANOG 
+Dox 
7 359 93.11 
(±3.4) 
36.53 (±18.4) 12.37 (±7.3) 7.75 (±18.6) 
EOG_TET_NANOG  
-Dox 
7 330 92.35 
(±7.5) 
42.15 (±11.1) 16.25 (±7.9) .8 (± .5) 
 
 
 
Figure 32: Blastocyst development for NT runs 1-7 of the EOG_TET_NANOG cell 
line on days 7 and 8. Grading criteria from Appendix 4 used. n= biological replicates, 
N= number of embryos analysed. Error bars represent ± SEM. Students t-tests were 
conducted to measure significance (P<0.05). 
Over 7 consecutive NT runs there were no significant differences in development 
between induced and the non-induced treatments. There was also no significant 
difference in both treatments between day 7 and day 8 development. This is why 
only the day 8 data is presented in the table, as this is the developmental day in 
which this project is most interested. The mCherry and GFP data was recorded 
and embryos were graded using a fluorescence microscope, the embryo was 
recorded as positive if any cell within the embryo expressed mCherry or GFP 
(Figure 33). 
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Figure 33: mCherry and GFP is higher than control on day 7 and day 8. n and N 
values (Figure 32). Visual analysis of mCherry and GFP signal. Error bars represent ± 
SEM. Fishers exact test was used to measure significance (P<0.05). * denotes 
significance P<0.05, ** denotes significance P<0.001 from control.  
For mCherry expression on day 7 and day 8, induced treatment is significantly 
higher than non-induced. GFP expression was significantly higher in the induced 
treatment on day 8 (P= 0.02). This trend was also true on day 7. However, was not 
significant on this day (P= 0.06). 
3.6.1 Significant increase in ectopic NANOG mRNA of FACS 
sorted NT embryos has no significant effects on 
pluripotency-related targets 
The EOG_TET_NANOG NT embryos were analysed for ectopic NANOG 
expression in comparison to their endogenously expressed NANOG. Analysis of 
XIST was also conducted and the embryos were analysed for a series of 
pluripotency genes, to determine whether these were affected by the additional 
NANOG present. These were SOX17, SOCS3, KLF4, FGF4, PDGFRα, 
respectively (Figure 34). 
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Figure 34: EOG_TET_NANOG embryos significantly overexpressed ectopic 
NANOG mRNA with no effects on pluripotency-related genes XIST, endogenous 
NANOG, SOCS3, FGF4, PDGFRα, SOX17 and KLF4. Blastocysts (grades 1-2) derived 
from 7 NT runs, cultured with and without  doxycycline were processed at day 8 via 
RNAGEM and cDNA synthesis in pools of 5-10 per sample. n= biological replicates N= 
number of embryos.  EOG_TET_NANOG +Dox. n= 5 N= 33. EOG_TET_NANOG -Dox 
n= 7 N= 36.The values of target genes were normalised against 18S in RU. These values 
were logged and averaged. Error bars indicate + SEM. Students t-test were conducted to 
measure significance (P<0.05). * denotes significance (P = 0.05) 
The expression of ectopic NANOG showed a 100-fold significant increase in the 
induced against non-induced control (P= 0.05). Endogenous NANOG was not 
affected.  FGF4 was higher in the induced treatment by 20-fold but this was not 
significant (P= 0.07). PDGFRα, SOX17, SOCS3, KLF4, OCT4 and SOX2, showed 
no difference between treatments. The absolute copy number of both ectopic and 
endogenous NANOG was calculated (Figure 35). 
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Figure 35: Copy number of endogenous and ectopic NANOG mRNA transcripts. 
Copy number was calculated using protocol outlined in section 2.2.11.1.4. Samples were 
normalised over embryo number. n= biological replicates n= number of embryos. 
EOG_TET_NANOG +Dox n= 3 N= 22 EOG_TET_NANOG –Dox n= 5 N= 27. Students 
t-test were conducted to evaluate significance. ** denotes P= <0.05. 
For copy number analysis, there was no significant difference between induced 
and non-induced for endogenous NANOG. The ectopic NANOG was significantly 
higher in the induced treatment (P= 0.005). When combined, these two transcripts 
result in a two-fold increase in total NANOG expression. 
3.6.2 Activation of the donor genome is initiated at day 3 
Embryos were visualised throughout development and live images were captured 
on the EVOS microscope (Figure 36). Observations occurred on day 2, day 3, day 
5, day 7 and day 8.  
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Figure 36: Live images of “+Dox” and “-Dox” embryos on days 2, 3, 5, 7, and 8 show 
activation of the donor genome at day 3. Images captured using EVOS microscope. 
All non-induced embryos remained negative for the duration of culture. The 
mCherry signal only became visible on day 3 of culture and intensified from then 
on. All embryos were recorded for their GFP and mCherry expression throughout 
culture. This data can be seen in a bar graph (Figure 37). 
 
Figure 37: Bar graph of mCherry (A.) and GFP (B.) expression from day 2 to day 8 
shown as a percentage (%) of viable embryos for NT run 7. n= biological replicates 
N= number of embryos. n= 1 EOG_TET_NANOG +Dox N= 10 EOG_TET_NANOG –
Dox N= 18.  
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In the induced treatment the number mCherry positive embryos is 0% at day 2. 
Day 3 is the first day in which any mCherry positive embryo is visualised and at 
day 5 the percentage of positive embryos has increased. By day 7 the number of 
mCherry positive embryos is near 100% whereas no mCherry embryo is ever 
reported in the non-induced treatment.  GFP is not observed up until day 7. The 
number of GFP embryos then increases at day 8 however, this difference is not 
significant (Figure 33). There is a significant increase in the induced and non-
induced treatments for GFP expression on day 8 (Figure 33).  
3.6.3 ICC for NT embryos could not detect increased NANOG 
protein although mCherry signal was detected throughout 
the embryo 
Embryos from the first NT run were stained for NANOG using the ICC protocol 
(section 2.2.14). A Donkey anti Mouse Alexa Fluor® 488 (green) secondary was 
used for the secondary staining. Unfortunately, the stain was not successful but 
images of Hoechst and mCherry signal were captured.  
 
Figure 38: mCherry expression was visualised throughout the EOG_TET_NANOG 
+ Dox embryo. Images were pseudo coloured using ImageJ software. Hoechst DNA stain 
(Blue), mCherry signal (Red) Merged image consist of mCherry and Hoechst merged 
channels using ImageJ software.  
The mCherry signal is in the endoplasmic reticulum (ER) of the cell which is 
clearly seen in the merged image (Figure 38). The mCherry signal seems more 
intense in the inner cell mass but this may be an artefact of the ICM being a dense 
population of cells. Cells are positive for mCherry throughout the embryo.  
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3.6.4 mCherry analysis shows induction during serum starvation 
carries over into embryo culture 
For NT run 2 cells were cultured with and without doxycycline and then were 
split into doxycycline and no doxycycline treatments during embryo culture. The 
first name of the treatment group relates to their treatment during serum starvation 
(+Dox or –Dox), the second name relates to their treatment during embryo culture 
(+Dox or –Dox). This was to see if there was any carryover of the mCherry signal 
from the serum starvation treatment into the embryo culture (Figure 39). 
 
Figure 39: Carryover of mCherry from serum starvation induction. Column graph of 
percentage of mCherry positive embryos for four treatments in NT run 2. n= 1 
Initially, mCherry signal was not detected in either population of embryos 
cultured without doxycycline. On day 5, there were positive embryos in the 
“+Dox, -Dox” treatment and still none in the “-Dox, -Dox” treatment. On day 3, 
the “+Dox, +Dox” treatment has a higher number of mCherry positive embryos 
but this trend is remains throughout embryo culture.  
 
Embryos from NT run 2 were co-stained for NANOG with an Donkey anti Mouse 
Alexa Fluor® 488 (green) secondary and SOX2 with a Donkey anti Goat Alexa 
Fluor® 568 (red) secondary. They were also stained for DNA with Hoechst. A 
composite image of all three stains was compiled (Figure 40). 
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Figure 40: Representative embryos for all treatments from NT run 2 ICC for 
NANOG and SOX2. Images were pseudo coloured using ImageJ software. Hoechst 
DNA stain (blue), NANOG stain with Alexa Fluor 488 (green), SOX2 stain with Alexa 
Fluor 568 and mCherry signal (red), composite image compiled by merge channels using 
ImageJ software. 
The green NANOG stain was not well defined and it was hard to determine a 
positive cell. NANOG cells were counted in a blind assay of three embryos per 
treatment. There were no significant differences between the treatments for the 
NANOG signal. The SOX2 stain worked well and is a good indicator for the 
number of ICM cells within the embryo (Figure 41). However, it did mask the 
mCherry signal which could not be analysed after this staining. 
 
Figure 41: SOX2 is not affected by NANOG overexpression. Students t-tests were 
conducted to measure significance (P<0.05). Error bars represent ± SEM. 
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There was no significant difference between the “+Dox, +Dox” and “-Dox, -Dox” 
treatments for SOX2 positive cells. 
3.6.5 GFP positive and GFP negative segregated embryos do not 
show different mRNA expression from pooled embryo 
analysis 
Once it had been identified that there was a significantly higher number of GFP 
positive embryos in the induced embryos, the GFP positive embryos were kept 
separate from GFP negative embryos for qPCR analysis (Figure 42). 
 
Figure 42: Analysis of cDNA of EOG_TET_NANOG +Dox separated into GFP 
positive and GFP negative treatments do not show differences in mRNA expression 
from pooled embryo analysis. cDNA was extracted from day 8 EOG_TET_NANOG 
+Dox GFP positive embryos and EOG_TET_NANOG +Dox GFP negative embryos in 
pools of 2-3 blastocysts per cDNA sample. n= biological replicates N= number of 
blastocysts. EOG_TET_NANOG +Dox GFP positive n=2 N= 8 EOG_TET_NANOG –
Dox GFP- n= 2 N= 7. Target gene values were normalised against 18S expression in RU. 
Results were logged and averaged. A. Ectopic NANOG, B. XIST. C. PDGFRα. D. SOCS3 
E. KLF4.  
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Unfortunately, this was only achieved in NT runs six and seven, meaning there 
were not enough samples for any statistical analysis. As a trend, there is two 
orders of magnitude lower expression of ectopic NANOG in the GFP negative 
embryos. No induced GFP negative embryos were able to produce an endogenous 
NANOG signal and could not be graphed. There was a higher expression of XIST 
in the GFP positive embryos by four orders of magnitude Figure 42 (B). SOCS3 
Figure 42 (D) was lower in the GFP negative treatment by eight orders of 
magnitude where KLF4 and PDGFRα were similar between the two treatments 
Figure 42 (C and E).  
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 Discussion Chapter 4:
 Introduction 4.1
The aim of this research study was to investigate the role of NANOG 
overexpression and its effects on pluripotency-related genes, and X-chromosome 
inactivation in bovine fibroblasts and fibroblast derived NT embryos. The Tet-On 
3G system was selected to induce this overexpression of NANOG. This system 
successfully overexpressed the ectopic NANOG sequence compared to controls in 
fibroblast and NT embryos. However, in terms of absolute copy number the 
increase was not sufficient to produce an effect on the eight pluripotency-related 
genes investigated or on the inactive X-chromosome.  
 Objective 1: Investigation of the effects of overexpression 4.2
of NANOG on pluripotency-related genes.  
4.2.1 Effects of NANOG overexpression on endogenous NANOG, 
OCT4, and SOX2 in fibroblast. 
Previous studies in which Nanog was overexpressed within a pluripotency 
network have been conducted in other species such as pig [115]. In the research 
conducted for this thesis, a significant increase in ectopic NANOG was achieved 
in the induced treatment, compared to the non-induced EOG_TET_NANOG and 
EOG_TET controls by four and ten orders of magnitude, respectively (Figure 17). 
This held true when converted into absolute copy number where the induced 
EOG_TET_NANOG was significantly higher than the EOG_TET_NANOG and 
EOG_TET non-induced controls by five and ten orders of magnitude (Figure 18). 
Non-induced EOG_TET_NANOG was five orders of magnitude higher than the 
non-induced EOG_TET control. 
 
Analysis of OCT4 and SOX2 via qPCR found that these were not affected in the 
fibroblasts (Figure 17). These results are in disagreement with a study which 
showed that porcine foetal fibroblasts transfected with NANOG overexpression 
vectors resulted in a five-fold increase in OCT4 expression [115]. This may be 
because the absolute amount of NANOG that was produced pTRE3G-mCherry 
vector is insignificant to what is required to stimulate the pluripotency network. 
The increase of NANOG expression in the porcine study was 2000-fold higher 
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than that of the control. At this level of expression a morphology change was seen 
when the cells became round and small [115]. This observation was not identified 
during induction of the EOG_TET_NANOG cell line (Andria Green, unpublished 
data). The increase seen in this study could have been greater than that achieved 
here, unfortunately the porcine paper did not present copy number data and was 
therefore not comparable. An alternative theory is that the bovine fibroblast may 
have a stronger mechanism for maintaining its differentiated state than that of an 
ICM cell or porcine foetal fibroblast. 
 
When the EOG_TET_NANOG cell line was originally FACS sorted for the 
mCherry signal, the resulting cell line was found to be 98% mCherry positive. 
When these were analysed via ICC it was found that the expression of mCherry 
was not homogeneous and there were only 55 ± 9 % mCherry positive cells 
(Figure 19 and Figure 20). The cell line analysed here is the same as what was 
initially tested after FACS, yet gives a lower level of mCherry positivity. This is 
theorised to be a result of the difference in technique as FACS can detect those 
cells that are only mildly positive for mCherry that the eye would ignore. It was 
also found that there were 58 ± 15% NANOG positive cells which were expressed 
heterogeneously. This difference between the two proteins is not significant but 
does show a discrepancy. NANOG is a quickly degraded protein which has a half-
life of 120 minutes [44] which could cause NANOG to be misrepresented in the 
ICC analysis. This would suggest that the actual number of cells able to produce 
ectopic NANOG is higher than what was observed. In conclusion to this, NANOG 
is present in the fibroblast cell line in the induced treatment and is absent in the 
non-induced controls, though ICC is not an accurate quantitative measure of 
detecting NANOG or mCherry positivity. Investigation needs to be conducted 
into the homogeneity of the cell line. 
4.2.2 Ectopic NANOG expression in serum starved fibroblast 
The process of serum starvation does result in mortality of the cells. The 
EOG_TET_NANOG cell line survived serum starvation at a rate of 41 ± 17%. 
The cells also flattened as they transitioned into the G0 cell cycle phase (Andria 
Green, unpublished data). The induction of NANOG did not affect the 
morphology of the cells during standard serum starvation conditions (Andria 
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Green, unpublished data). During the qPCR analysis of the serum starved cells it 
was found that there was significantly less ectopic NANOG in the induced serum 
starved treatment as opposed to the induced non-starved treatment by two orders 
of magnitude (P= 0.02) (Figure 28). This was expected as it has been 
characterised that cells in quiescence after serum starvation carry out less 
transcription and translation [131,132]. Although it does decrease the signal upon 
mRNA analysis, it is theorised that this decrease is homogenous throughout the 
population and does not actually decrease the percentage of cells that are capable 
of producing ectopic NANOG. Instead it decreases the amount each cell is capable 
of producing, overall lowering the total amount of ectopic  NANOG in the cDNA 
sample.  
 
This was confirmed in the ICC analysis of the serum starved versus non-starved 
cells (Figure 29). Both induced starved and induced non-starved treatments 
contained 68 % mCherry positive cells, which showed that the percentage of cells 
capable of transcribing the pTRE3G-mCherry vector was not changed by the 
serum starvation treatment. Unexpectedly, when expressed as a percentage the 
NANOG positive cells increase significantly after serum starvation. This may be 
because the process of serum starvation causes a large proportion of cell death. It 
may be that the cells that survive starvation treatment were those that were in a 
better condition and were therefore more likely to successfully transcribe and 
translate the pTRE3G-mCherry vector sequence. Overall, it was shown that the 
fibroblasts were able to successfully transcribe and translate the vector sequence 
under serum starvation conditions. This validates the cells in their use in NT 
cloning.  
4.2.3 Effects of hygromycin selection on serum starved fibroblast  
In an attempt to increase the number of NANOG positive cells within the 
EOG_TET_NANOG cell line under induction, the cells were cultured with the 
antibiotic hygromycin during serum starvation. It was thought that all transfected 
cells would contain hygromycin resistance, regardless of induction. Induced and 
non-induced treatments were expected to have some cell death as a result of the 
serum starvation and also a percentage of death from the presence of hygromycin. 
However, it was found that the cells in the non-induced treatment under 
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hygromycin selection had a 100 % mortality rate (Figure 31). This was 
unexpected as although the hygromycin resistance plasmid would have integrated 
into the same locus as the pTRE3G-mCherry plasmid, it should have not been 
doxycycline-inducible. Both hygromycin resistance and pTRE3G-mCherry 
plasmids contain the SV40 promotor. It was hypothesised that the induction of the 
pTRE3G-mCherry plasmid had a wider control of the entire locus, resulting in an 
inducible hygromycin resistance.  
4.2.4 NANOG’s effect within the NT embryo  
It was hypothesised that the overexpression of NANOG would interact within the 
pluripotency network and would promote the pluripotency triumvirate SOX2, 
OCT4 and NANOG itself.  NANOG has a feedback loop in which it can promote 
or suppress its own expression. With the primers for ectopic and endogenous 
NANOG it was possible to analyse whether this feedback loop was stimulated by 
the ectopic NANOG causing expression or suppression of endogenous NANOG. It 
was also hypothesised that the additional NANOG would interact with other 
targets such as SOX17, PDGFRα, FGF4, SOCS3, and KLF4. 
 
When the new series of NT experiments were conducted after FACS, the 
timeframe of the activation of the donor genome was investigated. This was easily 
monitored by the mCherry signal. On days 2, 3, 5, 7 and 8, all induced and non-
induced embryos were visualised for their mCherry signal (Figure 36). The 
non-induced treatment remained negative for mCherry throughout the 8 days. The 
induced treatment was initially found to be mCherry negative on day 2 (4 cell). At 
day 3 (8 cell), the mCherry signal began and strengthened until it was its most 
intense signal at days 7 and 8 (blastocyst). This is consistent with literature 
showing that after fertilisation the oocyte carries out all transcription and 
translation until day 2 where it activates the donor genome [133]. However, it is 
still possible that residual mCherry produced during serum starvation could be 
concentrated during cleavages until it becomes visible on day 3 (8 cell) and then 
increases in strength with each cleave. To disprove this possible theory that the 
mCherry signal in the induced treatment could be residual from the induction 
during serum starvation, NT run 2 was conducted.  
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For the purposes of these experiments, the first name of the treatment group 
relates to their treatment during serum starvation (+Dox or –Dox), the second 
name relates to their treatment during embryo culture (+Dox or –Dox). The 
“+Dox, -Dox” treatment had low levels of residual mCherry expression 
throughout embryo culture; this was seen in less than 15% of embryos from days 
3-8 (Figure 39). The “+Dox, +Dox” treatment had greater than 80% positive 
embryos from day 3 and by day 8 this was 100%. The “-Dox, +Dox” embryos 
were positive for mCherry at nearly the same rates as “+Dox, +Dox” (91% at day 
8) which shows that this signal could only have been produced during embryo 
culture. To conclude, there is some signal that remains from induction during 
serum starvation but that the embryo is capable of producing mCherry. 
 
The mCherry signal within the embryo was photographed in comparison to a 
DNA stain in Figure 38. When comparing that image to the images taken of the 
analysis of the fibroblast cells, some differences were observed. In the fibroblasts, 
mCherry signal was very strong in the nucleus and weak in the cytoplast (Figure 
19) whereas the embryo’s mCherry signal is absent from the nucleus and is highly 
concentrated in the ER (Figure 38). The results from NT run 2 show that the 
embryo is capable of producing mCherry during embryo culture. These images 
indicate that the mCherry protein is processed differently within the cells of the 
embryo compared to the fibroblast. 
 
The developmental data of each EOG_TET_NANOG NT run was recorded and 
analysed. It was a possibility that the additional NANOG may increase the quality 
of embryos or the absolute numbers by helping them reach a naïve pluripotent 
state more easily. Alternatively, additional NANOG may have a detrimental effect 
on the embryo. NANOG is usually isolated to the ICM and cells of the trophoblast 
expressing NANOG may be incapable of normal formation. It was found that 
there was no significant difference between the induced and non-induced 
treatments in blastocyst number or quality (Figure 32 and Table 18). This 
indicates that the culture in doxycycline does not have an effect, which has been 
seen in previous studies [134]. It also means that the additional NANOG did not 
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have a beneficial or detrimental effect on the embryos development. This was also 
seen in the overexpression of NANOG in porcine [115].   
 
In the NT embryo, when comparing just the expression of ectopic NANOG there 
was a 100-fold significant increase in the induced treatment compared to the 
non-induced control (Figure 34). However, when the copy number of endogenous 
NANOG and ectopic NANOG were calculated, the scale of the additional total 
NANOG was illuminated. The total amount of additional NANOG produced was 
increased at physiological by two-fold (Figure 35). This is comparable to what is 
seen when the bovine embryo was cultured in 2i, which saw a two-fold NANOG 
increase [37,38]. With the increase in total NANOG achieved here it could be 
assumed that a similar effect to 2i culture may result.  
 
Using ICC, there was no clear NANOG staining of any NT embryo examined 
(Figure 40). Of the stainings that were achieved, there was no significant 
difference between induced and non-induced treatments. A successful SOX2 
staining was conducted (Figure 40). SOX2 identifies the cells of the ICM [135]. 
With additional NANOG, it could be possible to observe an increase in the 
number of SOX2 positive cells by increasing the size of the ICM. This would 
indicate that the additional NANOG has interacted with the pluripotency network 
to increase its function. Results showed that there was no significant increase in 
the induced treatment in the number of SOX2 positive cells. This correlates with 
the qPCR data. 
 
When the analysis of ectopic NANOGs was conducted it was found that there was 
no effect on the expression of endogenous NANOG (Figure 34). It was not 
suppressed nor was it up-regulated in the induced treatment compared to control. 
This indicates that the additional NANOG from the pTRE3G-mCherry vector does 
not stimulate or supress the feedback loop for endogenous NANOG. In addition, 
when OCT4 and SOX2 were investigated it was found that there was no effect on 
their expression (Figure 34). When NANOG was overexpressed in porcine 
embryos the NANOG was able to up-regulate the expression of endogenous 
NANOG, SOX2 and OCT4 [115]. This supports the theory that the increased 
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NANOG produced here, is either incapable of stimulating the function of the core 
pluripotency network or is too insignificant. 
 
Pdgfrα and Sox17 are markers differentiation and for the hypoblast [117,118]. 
These markers were hypothesised to decrease in expression after exposure to 
increased NANOG as the additional NANOG may decrease the size of the 
hypoblast [37]. After qPCR analysis of seven NT cDNA samples per treatment, it 
was found that there was no significant difference between the induced and non-
induced treatments for both genes (Figure 34). This indicates that the increased 
NANOG did not have an effect of the fate of the cells. It could not prevent them 
from differentiating into hypoblast. This does not correlate with recent bovine 
studies where the use of 2i increased NANOG two-fold, and also down-regulated 
both SOX17 and PDGFRα [37]. This could be a flow on effect from what is seen 
in the analysis of endogenous NANOG, SOX2 and OCT4. Since the core 
pluripotency network was not affected it is unlikely that pluripotency-related 
genes would be effected either.  
 
Klf4 binds directly to the promotor region of Nanog [116] and is one of the four 
factors required in the dedifferentiation of cells used in iPS cell generation 
[28,29]. It was theorised that the increase in NANOG would increase the 
expression of KLF4. However, it was found that there was no difference between 
the induced and non-induced treatments for KLF4 expression (Figure 34). This 
again may be because of a lack of ability to increase the NANOG protein, 
ultimately making it impossible to increase NANOG function. Socs3 is a 
differentiation marker that negatively regulates the LIF pathway [120]. It is 
down-regulated by Nanog and results in an enhanced LIF signal transduction. 
Therefore, with the additional NANOG a decrease would be expected in SOCS3 
expression. Yet like all other pluripotency-related genes investigated here, there 
was no change in SOCS3 expression between the induced and non-induced 
treatments (Figure 34). 
 
The only gene investigated which did show a difference between treatment groups 
was FGF4 (Figure 34). This was higher in the induced embryos by a 20-fold 
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increase compared to non-induced control. However, this was not significant 
(P= 0.07). This does correlate with 2i effects on bovine embryos where both 
NANOG and FGF4 were up-regulated simultaneously [37]. This does indicate that 
there may be a  effect of additional NANOG protein within the embryo, although. 
 
There were a high proportion of GFP positive embryos in the induced treatment in 
comparison to non-induced control on day 7 of embryonic development. By day 8 
this difference became significant (P= 0.02) (Figure 33). It was then theorised that 
those embryos that were successfully producing a large amount of ectopic 
NANOG were switching on the OCT4-GFP reporter system from the parental line 
EOG. GFP positive embryos were then analysed separately from GFP negative 
embryos. Due to time constraints, not enough NT runs could be conducted to 
produce the samples required for statistical analysis. However, some preliminary 
analysis was still conducted. When analysing the trends seen in the column graphs 
of Figure 42, the expression of ectopic NANOG does not change compared pooled 
GFP positive and negative samples. The endogenous NANOG could not be 
detected in the induced GFP negative embryos, which could be an interesting 
insight into their pluripotent state. There was an increase by four orders of 
magnitude in XIST and in SOCS3 by eight orders of magnitude in GFP positive 
embryos compared to GFP negative controls. There is no change between the two 
treatments in the analysis of PDGFRα or KLF4 (Figure 42) which indicates that 
the outer pluripotency network is again not affected. Although this data is not yet 
conclusive due to sample size, it does indicate that the theories of the OCT4-GFP 
reporter being stimulated by the additional NANOG are not valid.  
 
In the experiments conducted for the purposes of this thesis, the mCherry signal 
was near 100% in induced embryos on day 8. This means that the 
pTRE3G-mCherry sequence was active in all embryos analysed. It has also been 
conclusively proven the mRNA of the total overexpression of NANOG was 
two-fold. What was unclear was whether the NANOG protein was overexpressed. 
The pTRE3G-mCherry vector construct encodes mCherry before NANOG (Figure 
8). It has been identified that there are some issues with the IRES system, in that, 
it may fail to initiate separate protein production resulting in fusion proteins [136]. 
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It can also cause unpredictability in the expression of the vector [136]. It may be 
possible that some mCherry positive embryos are not efficiently transcribing the 
NANOG section of the vector sequence. This would be the reason why the qPCR 
data indicates a significant overexpression of ectopic NANOG where no additional 
NANOG protein has been identified via ICC (Figure 40). This may be the cause 
the of lack of effect. The two effects identified in the induced embryos are the 
significantly increased GFP signal and the increase in FGF4 expression which is 
not significant (P= 0.07). If the NANOG protein is not efficiently translated this 
may be the reason for such mild effects. Conclusive evidence for the 
overexpression of the NANOG protein needs to be achieved to verify if the 
NANOG protein is sufficiently overexpressed by the Tet-3G vector system. 
 Objective 2: NANOG’s effect on XIST expression 4.3
It was also theorised that NANOG would have an effect on XIST. During the 
development of pluripotency in mouse, Nanog down-regulates Xist. It was 
proposed that this would hold true in the bovine system and would decrease the 
level of XIST detected via qPCR analysis. It could extend the period of double 
X-chromosome activation as well as potentially improving the removal of the 
XIST cloud. 
 
When XIST was analysed via qPCR of eight cells lines, it was found that the 
female cell lines had significantly higher XIST expression in comparison to two 
male controls (Figure 24). XIST was found not to decrease in the presence of 
increased NANOG, which is not usually present within the fibroblast system. The 
induced treatment did not have significantly less XIST expression than the other 
female cell lines and remained significantly higher than the male controls. This 
shows that the additional NANOG achieved in these assays in the induced 
treatment does not down-regulate XIST in the fibroblasts at any measurable level. 
This may be because the X-chromosome dosage compensation is required to such 
a high level that the mechanisms that hold the inactive X-chromosome in place 
within the fibroblast are much stronger than that of the ICM. 
 
There were many difficulties encountered during the analysis of XIST expression, 
many of which were a result of the fact that XIST is a lnc-RNA. There have been 
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many instances in which teams have achieved successful staining of Xist using 
techniques such as RNA in situ hybridisation and a standardised protocol in 
human pluripotent stem cells has been established [137]. Successful assays have 
also been achieved in bovine [130]. For the purposes of this research the 
ViewRNA
TM
 ISH Cell Assay for RNA FISH kit was used [138]. This technique 
had high sensitivity and could bind to a single RNA molecule. It also had the 
ability to perform multiplexing which was essential for these assays as the 
localisation of NANOG and XIST was required simultaneously. The positive 
controls provided by the kit produced some colour signal after conducting some 
preliminary experiments, but no signal was detected for the bovine cell line 
samples after multiple attempts. This method was then excluded from potential 
XIST visualisation options for the purposes of this thesis. 
 
There are a number of protein stains that can evaluate the inactive X-chromosome. 
An Eed stain was conducted by Professor Austin Smith’s team to produce the 
embryo images seen in Figure 5 [31] . Eed is a component of the Eed-Enx1 
Polycomb group complex, which Xist recruits to attain methylation markers on the 
inactive X-chromosome [54], therefore staining for the Eed protein achieves a 
proxy stain to the inactive X-chromosome [31]. However, this method was not 
available as previous experiments conducted using this antibody showed that the 
Eed antibody did not reliably co-react with the bovine protein (Prasanna Kumar 
Kallingappa, Unpublished data). Instead, an equally valid H3K27me3 staining was 
attempted. This also identifies the inactive X-chromosome as the Xist cloud 
collaborates the epigenetic silencing of the inactive X-chromosome through the 
use of methylations such as H3K27me3 [55]. Because of this, H3K27me3, although 
present throughout the nuclei is highly concentrated around the inactive X-
chromosome [55].  
 
The ICC assay has been successfully achieved in human and bovine for H3K27me3 
as a good proxy stain for the inactive X-chromosome [130]. In studies previously 
conducted in this group, this assay was successful using a specific antibody that 
recognises only one epitope of H3K27me3 [139]. This polyclonal antibody was a 
finite resource and was no longer available by the time this project commenced. 
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Instead, two commercially available antibodies were analysed. Both of these 
produced a positive signal throughout the nuclei but neither were successful in the 
identification of the inactive X-chromosome (Figure 25)(Only the data of one 
antibody was presented). This assay was conducted on the induced and non-
induced treatments of the EOG_TET_NANOG cell line. A series of controls were 
also run of confirmed female and male cell lines (section 3.4.1) this included the 
two parental cell lines, of EOG_TET_NANOG, EOG_TET and EOG as well as 
two unrelated female cell lines, LFC2 and EFC1B, and an unrelated male cell line, 
LJ801. The results of the staining showed some potential inactive 
X-chromosomes (Figure 26). Counting analysis of these potential inactive 
X-chromosome H3K27me3 “clouds” showed that the female cells did not have 
significantly higher number of “clouds” than the male control group (Figure 27). 
This indicates that the spots which were thought to potentially be inactive 
X-chromosomes were just an artefact of the stain. Throughout this project there 
was never a confirmed inactive X-chromosome. This may be a result of the cell 
line used. After a review of the literature, it was confirmed that no studies have 
been conducted on fibroblasts as most are investigating the inactive 
X-chromosome were within the ES cell or embryo. It could be possible that the 
inactive X-chromosome is not present in the fibroblast. 
 
XIST does not only interact with NANOG, it interacts with the entire pluripotency 
network [46]. It was hypothesised that the additional NANOG would be able to 
decrease XIST in the NT embryo, but for this to have been achieved an increase of 
the core pluripotency network may have been required. When XIST was 
investigated using qPCR in NT embryos it was found that XIST was not down-
regulated by the additional NANOG (Figure 34). This was not surprising as the 
core pluripotency network (OCT4, SOX2 and endogenous NANOG) was not 
stimulated. When the NT embryos were separated into GFP positive and GFP 
negative embryos for qPCR analysis the trend seen in XIST expression did not 
change. NANOG does have a direct interaction with XIST and may be able to 
supress XIST on its own. However, it remains unclear how much additional 
NANOG protein was achieved in these assays and it may be possible that the 
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additional protein was incapable and/or too insignificant to produce a functional 
change.  
 Efficiency of the Tet-On-3G system 4.4
The Tet-On 3G system was the system selected for overexpression. One reason 
this system was chosen was its capability to be turned on or off in the presence or 
absence of doxycycline. This was essential for use in the embryo as it meant the 
transgene could be controlled temporally. The decision was made to induce 
throughout embryo culture after previous experiments (data not shown) had 
determined no effect on the time of induction.  
 
There have been a number of instances in which the Tet-On 3G system has been 
used in fibroblasts and in NT embryos. In 2006, a proof-of-principle experiment 
was conducted in porcine [134] using a vector sequence containing enhanced GFP. 
The aim of this study was to show that a gene that may be detrimental to cells, or 
early embryos at different stages could be switched on or off depending on what 
was required. This experiment proved that the system could be controlled very 
tightly temporally, although there was some leaky expression which they could 
not control [134]. They suggest improvements to the leakiness of the system 
without compromising the expression of the gene of interest. In the analysis of the 
EOG_TET_NANOG fibroblasts there was a significant increase in expression in 
the non-induced EOG_TET_NANOG treatment when compared to EOG_TET. 
This suggested that the leaky expression of this system was still a problem. It may 
mean that the non-induced control was not a sufficiently silenced comparison for 
gene regulation in the NT embryo and that an EOG_TET NT embryo would be a 
more reliable control. It is also crucial that characterisation of the NANOG 
protein levels within the NT embryo occurs, as there is no evidence that NANOG 
protein was overexpressed.  
 Conclusion 4.5
In conclusion, the Tet-On 3G system could produce a significant increase in the 
expression of ectopic NANOG in bovine fibroblasts by four orders of magnitude. 
In NT embryos total NANOG was increased two-fold. There were no significant 
effects on the expression of the eight pluripotency-related genes investigated; 
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endogenous NANOG, OCT4, SOX2, KLF4, FGF4, SOX17, PDGFRα, and SOCS3 
in NT embryos. The expression of XIST was also not affected by the additional 
NANOG. No inactive X-chromosomes were detected via ICC, meaning that a 
direct comparison of localisation of expression of XIST and NANOG could not be 
achieved. There was no evidence for the presence of additional NANOG protein 
in induced embryos compared to controls. 
 Recommendations for future work 4.6
In the future, the clonality of the EOG_TET_NANOG cell line should be 
investigated. If one cell is strongly NANOG positive any daughter cell should also 
be strongly positive. Towards the end of this project some single cell colonies 
were derived from EOG_TET_NANOG. These cells should be stained for 
NANOG via ICC to see if they are homogeneously NANOG positive or if the 
resemble the results produced from the current EOG_TET_NANOG cell line. 
This will give insight into the function of the pTRE3G-mCherry vector and if it is 
stably expressed. Also, the expression of the pTRE3G-mCherry vector throughout 
the embryo needs to be investigated. Analysis of the trophectoderm in comparison 
to the ICM will illuminate issues that may arise with NANOG expression in 
tissues that it is not commonly expressed in. These tissues may possess alternative 
NANOG processing or the presence of NANOG could be detrimental to them. 
Effects of the temporal expression of NANOG should also be evaluated as it is 
only transiently expressed within the ICM and a thorough investigation of its 
constant expression will also reveal NANOG processing and or functional aspects. 
Further investigation should be conducted into the expression of the pTRE3G-
mCherry vector and its IRES, because there was no evidence that there was any 
additional NANOG protein in the induced NT embryos.  
 
There have been recent advances in the methods used for establishing genetic 
modifications. Some of these entail cytoplasmic injection which avoids the 
artefacts of NT cloning, but need to be carefully characterised for their efficiency 
of dispersal throughout the embryo before they can be used effectively. The most 
promising of these is the clustered regularly interspaced short palindromic repeats 
(CRISPR)/Cas9 system. This is an aspect of the bacterial immune system which 
evolved to defend against phages and plasmids [140]. It works by creating double 
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stranded breaks at a specific site in the genome. This system could be utilised by 
adapting the genetic sequence used to target specific sites in the genome. These 
breaks can then be used to genetically modify the sequence [141]. This 
CRISPR/Cas9 system has been investigated in livestock and has provided 
efficient new means of derivation of transgenic animals. [141]. Over other 
methods this technique has many advantages. The CRISPR/cas9 system is easy to 
use and has a fast protocol, it also has high-specificity DNA recognition [142]. A 
protocol has been established for using CRISPR/Cas9 in the generation of 
overexpression systems [143]. It can target the promotor of a gene and modulate 
endogenous gene expression. Human cancer cells were transfected with 
single-guide RNAs which targeted the promotor of Nanog. They were able to 
achieve a two-fold increase in Nanog expression [143]. This systems can also be 
applied in a multiplex, overexpressing or suppressing the expression of multiple 
genes simultaneously [143]. This will aid the understanding of complex molecular 
systems such as the pluripotency network. Future work similar to what was 
conducted in this thesis should be via the use of this system. 
 
Another improvement would be in the genetic analysis of mRNA. The RNAGEM, 
cDNA synthesis protocols result in 21 µL. The current method of qPCR analysis 
requires between 1-2 µL of sample per gene analysed. This severely limits the 
number of genes that can be analysed. If a robust overexpression of NANOG was 
successfully established, single embryo analysis would be a better form of 
evaluation. There have been advances in the field of genetic analysis, for example 
the development of next generation sequencing. This has increased the rate at 
which experiments can be conducted, by analysing huge numbers of genes from 
just one sample. Soon this technology will become more available and could be 
more widely applied. Recent studies in New Zealand have used new technologies 
[37] such as the Nanostring nCounter technique. This offers gene expression 
analysis of up to 800 genes on one sample with a sensitivity that can detect one 
molecular copy per cell. For the NT embryo system this would identify target 
genes more efficiently from small sample numbers [144].  
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Appendices  
Appendix 1: Fusion record sheet. 
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Appendix 2: mCherry and GFP embryo grading sheet. 
 
Appendices 
120 
 
Appendix 3: Embryo grading record sheet. 
 
Appendix 4: Embryo grading regulations 
Images from “Manual of the International Embryo Transfer Society” (3rd edition). Edited 
by David A. Stringfellow and Sarah M. Seidel. Published April 1988, International 
Embryo Transfer Society, 1111 North Dunlap Ave, Savoy, IL, USA. 
 
When applied for the purposes of this research; 4= Tight Morula (TM), 5= Early 
blastocyst (EM), 6= Blastocyst (B), 7= expanded blastocyst (EB) and 8= hatched 
blastocyst (HB). The cycle day is the equivalent day at which the stage code would 
develop after fertilisation. Quality code or grade (1-3) is based on morphological 
characteristics depicted in each corresponding image. Comments about reasoning of 
morphological grade identified by the manual are presented as stated below. 
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Comments:  
d) Single or small blastomeres comprise less than 15% of the total cellular material and the 
embryo is consistent with the expected stage of development.  
e) Sperm on zona pellucida.  
f) Embryos with many extruded cells or debris must be carefully rolled over to determine the 
presence and quality of any viable embryo mass.  
g) Quality code 3 embryos have an embryo mass that is less than 50% of all cellular material 
within the zona pellucida.  
h) This embryo has a nice but very small mass. If the embryo mass is less than 25% of all cellular 
material, it should be given a code 4 (non-viable).  
i) Irregular shape is a common variation in blastocoel development. 
j) Collapsing of the blastocoel is considered a normal physiological process that does not lower the 
quality grade.  
k) Extruded cells in stage code 6, 7, and 8 embryos are often pressed against the zona pellucida 
and not obvious unless the embryo has collapsed due to normal physiological processes or when 
cryoprotective additive is introduced.  
l) This embryo has a flat (even concave) surface of the zona pellucida that can cause the embryo to 
stick to the petri dish or straw. This defect alone keeps the embryo from being classified as quality 
grade 1 and should not be utilised in international commerce unless agreements allow for other 
than quality code 1 embryos.  
m) Cellular debris on the surface of the zona pellucida shows that this embryo has not been 
washed by proper procedures.  
n) This embryo has a cracked zona pellucida at the top of the picture. Embryos that do not have an 
intact zona pellucida should not be utilised in international commerce. 
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